EP1663966A1 - 1,3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases - Google Patents

1,3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases

Info

Publication number
EP1663966A1
EP1663966A1 EP04765174A EP04765174A EP1663966A1 EP 1663966 A1 EP1663966 A1 EP 1663966A1 EP 04765174 A EP04765174 A EP 04765174A EP 04765174 A EP04765174 A EP 04765174A EP 1663966 A1 EP1663966 A1 EP 1663966A1
Authority
EP
European Patent Office
Prior art keywords
formula
alkyl
compound
chloro
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04765174A
Other languages
German (de)
French (fr)
Other versions
EP1663966B1 (en
Inventor
Darren M. Novartis Horsham Research Ctr. LE GRAND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0321600A external-priority patent/GB0321600D0/en
Priority claimed from GB0321599A external-priority patent/GB0321599D0/en
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Priority to PL04765174T priority Critical patent/PL1663966T3/en
Publication of EP1663966A1 publication Critical patent/EP1663966A1/en
Application granted granted Critical
Publication of EP1663966B1 publication Critical patent/EP1663966B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to organic compounds, their preparation and their use as pharmaceuticals.
  • the invention provides compounds of formula la or lb
  • Ar is phenyl optionally substituted by one or more substituents selected from halogen, Ci-Cs-alkyl, cyano or nitro;
  • R 1 is hydrogen or Ci-Cs-alkyl optionally substituted by hydroxy, Ci-Cs-alkoxy, acyloxy, halogen, carboxy, Ci-Cs-alkoxycarbonyl, -N(R 4 )R 5 , -CON(R 6 )R 7 or by a monovalent cyclic organic group having 3 to 15 atoms in the ring system;
  • Q has the formula R a / ⁇ C— C — where R a is Ci-Cs-alkylene, or Q is -C(R b )(R c )- where R b and R c are independently Ci-Cg-alkyl or R b and R c together form a C 3 -C ⁇ o-cycloalkyl; Y is oxygen or sulfur;
  • R 2 is hydrogen, Ci-Cs-alkyl or C3-C ⁇ o-cycloalkyl and R 3 is Ci-Cs-alkyl substituted by phenyl, phenoxy, acyloxy or naphthyl, or R 3 is C 3 -C ⁇ o-cycloalkyl optionally having a benzo group fused thereto, a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms, phenyl or naphthyl, said phenyl, phenoxy or naphthyl groups being optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, acyl, nitro, -SO 2 NH 2 , Ci-Cs- alkyl optionally substituted by Ci-Cs-alkoxy, Ci-Cs-haloalkyl, Ci-Cs-alkoxy, Ci-Cs- haloalkoxy, Ci-Cs-alkylthio, -SO
  • R 4 and R 5 are each independently hydrogen or G-Cs-alkyl, or R 4 is hydrogen and R 5 is hydroxy-Ci-Cs-alkyl, acyl, -SO 2 R 8 or -CON(R 6 )R 7 , or R 4 and R 5 together with the nitrogen atom to which they are attached denote a 5-or 6-membered heterocyclic group;
  • R 6 and R 7 are each independently hydrogen or Ci-Cs-alkyl, or R 6 and R 7 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group;
  • R 8 is Ci-Cs-alkyl, Ci-Cs-haloalkyl, or phenyl optionally substituted by Ci-Cs-alkyl.
  • Ci-Cs-alkyl denotes straight chain or branched alkyl having 1 to 8 carbon atoms.
  • Ci-Cs-alkyl is C ⁇ -C 4 -alkyl.
  • Ci-Cs-alkylene denotes straight chain or branched alkylene that contains 1 to 8 carbon atoms.
  • G-Cs-alkylene is G-C 4 -alkylene, especially straight chain butylene.
  • C3-C ⁇ o-cycloalkyl denotes cycloalkyl having 3 to 10 ring carbon atoms, for example a monocyclic group such as a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, any of which can be substituted by one or more, usually one or two, C ⁇ -C -alkyl groups, or a bicyclic group such as bicycloheptyl or bicyclooctyl.
  • C 3 -C ⁇ o-cycloalkyl is C 3 -C6-cycloalkyl, especially cyclopropyl or cyclobutyl.
  • Ci-Cs-alkoxy denotes straight chain or branched alkoxy having 1 to 8 carbon atoms.
  • Ci-Cs-alkoxy is G-C -alkoxy.
  • Ci-Cs-haloalkyl denotes Ci-Cs-alkyl as hereinbefore defined substituted by one or more halogen atoms, preferably one, two or three halogen atoms.
  • Ci-C ⁇ -haloalkoxy denotes C ⁇ -C 8 -alkoxy as hereinbefore defined substituted by one or more halogen atoms, preferably one, two or three halogen atoms.
  • Aminocarbonyl as used herein denotes amino attached through the nitrogen atom to a carbonyl group.
  • Ci-Cs-alkylamino and di(C ⁇ -C8-alkyl)amino are respectively C ⁇ -C - alkylamino and di(C ⁇ -C -alkyl)amino.
  • C ⁇ -C8-alkylaminocarbonyl and "di(C ⁇ -Cs-alkyl)aminocarbonyl” as used herein denote aminocarbonyl as hereinbefore defined substituted respectively on the nitrogen atom by one or two Ci-Cs-alkyl groups as hereinbefore defined, which may be the same or different.
  • C ⁇ -C8-alkylaminocarbonyl and di(G-C8-alkyl)aminocarbonyl are respectively G-C -alkyl- aminocarbonyl and di(C ⁇ -C -alkyl)aminocarbonyl.
  • G-Cs-alkyl thio as used herein denotes Ci-Cs-alkyl as hereinbefore defined linked to -S-.
  • Acyl denotes alkylcarbonyl, for example G-Cs-alkylcarbonyl where G-Cs- alkyl may be one of the G-Cs-alkyl groups hereinbefore mentioned, optionally substituted by one or more halogen atoms; cycloalkylcarbonyl, for example C 3 -C8-cycloalkylcarbonyl where C 3 -C8-cycloalkyl may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; 5- or 6- membered heterocyclylcarbonyl having one or two hetero atoms selected from nitrogen, oxygen and sulfur in the ring, such as furylcarbonyl or pyridylcarbonyl; arylcarbonyl, for example G-Go-arylcarbonyl such as benzoyl; or aralkylcarbonyl, for
  • Acyloxy denotes alkylcarbonyloxy, for example G-Cs-alkylcarbonyloxy where G-Cs-alkyl may be one of the G-Cs-alkyl groups hereinbefore mentioned, optionally substituted by one or more halogen atoms; cycloalkylcarbonyloxy, for example G-Cs-cyclo- alkylcarbonyloxy where G-Cs-cycloalkyl may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; 5- or 6- membered heterocyclylcarbonyloxy having one or two hetero atoms selected from nitrogen, oxygen and sulfur in the ring, such as furylcarbonyloxy or pyridylcarbonyloxy; arylcarbonyloxy, for example C6-Go-arylcarbonyl- oxy such as benzoyloxy;
  • acyloxy is G-C -alkylcarbonyloxy, or benzoyloxy or phenoxy-G-C - alkylcarbonyloxy. optionally substituted in the benzene ring thereof by at least one substituent selected from G-C -alkoxy, G-C 4 -alkylcarbonyl or aminosulfonyl.
  • Halogen as used herein may be fluorine, chlorine, bromine or iodine; preferably it is fluorine, chlorine or bromine.
  • G-C ⁇ -alkoxycarbonyl denotes G-Cs-alkoxy as hereinbefore defined attached through the oxygen atom to a carbonyl group.
  • Di-(G-Cs-alkyl)aminocarbonylmethoxy denotes aminocarbonylmethoxy disubstituted on the amino nitrogen atom by G-Cs-alkyl as hereinbefore defined, the two G-Cs-alkyl groups being the same or different.
  • Optionally substituted means the group referred to can be substituted at one or more positions by any one or any combination of the radicals listed thereafter.
  • the phenyl group may be substituted, for example by one, two or three, preferably one or two halogen atoms, preferably selected from fluorine and chlorine atoms, or by one or two G-Cs-alkyl, cyano or nitro groups, or by G-Cs-alkyl and one or two halogen, preferably fluorine or chlorine, atoms.
  • one halogen substituent it is preferably para to the indicated group X 1 or X 2 .
  • there are two or three halogen substituents preferably one is para to the indicated group X 1 or X 2 and at least one of the others is ortho to the para-halogen substituent.
  • R 3 as substituted phenyl may, for example, be substituted by one, two, three, four or five, preferably by one, two or three, of the abovementioned substituents.
  • R 3 may be, for example, phenyl substituted by one, two or three substituents selected from halogen, cyano, hydroxy, nitro, G-G-alkoxy, G-C -alkoxycarbonyl, G-C 4 -haloalkoxy, -CO-NH 2 , di(G-C -alkyl)- aminocarbonylmethoxy, G-C -alkyl optionally substituted by G-C -alkoxy, G-C -haloalkyl, G-C -alkylcarbonyl, G-C 4 -alkylthio, -SO 2 -NH 2 , -SO 2 -G-C 4 -alkyl, di(G-C 4 -alkyl)amino, G- C -al
  • R 3 as substituted phenyl is preferably phenyl substituted by one or more substituents selected from cyano, halogen, G-C -alkyl optionally substituted by G-C -alkoxy, G-C 4 -alkylcarbonyl, G-C 4 -alkoxy, G-C -alkoxy- carbonyl, -CO-NH2, -SO 2 -NH 2 , -SO 2 -G-C -alkyl, G-C 4 -alkyl-aminocarbonyl, di(G-C 4 -alkyl)- aminocarbonyl-methoxy or G-C 4 -alkyl-carbonylamino, especially cyanophenyl, particularly meta-cyanophenyl, and disubstituted phenyl where one substituent is G-C -alkoxy or di(G- C -alkyl)aminocarbonylmethoxy, preferably ortho to the bond linking R 3 to the remainder
  • R 3 is G-C -alkyl substituted by optionally substituted phenoxy
  • the substituent(s) on phenoxy may be, for example, one, two or three substituents selected from halogen, cyano, G-Cs-alkyl, G-G-alkoxy or G-G-alkyl- carbonyl.
  • R 3 as a heterocyclic group may be, for example, a group having 5 to 11 ring atoms of which one, two, three or four, preferably one or two, are hetero atoms selected from nitrogen, oxygen or sulfur, such as pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyranyl, pyrazinyl, or a 5-, 6- or 7-membered heterocyclic, ring preferably having one or two oxygen or nitrogen ring atoms, fused to a benzene ring, said heterocyclic group being optionally substituted by substituents including halogen, G-C 4 -alkyl optionally substituted by G-C -alkoxy, G-C -alkoxy, -SO 2 -C ⁇ -Cs-alky
  • a heterocyclic group having 5 to 11 ring atoms of which one, two, three or four, preferably one or two, are hetero atoms selected from nitrogen, oxygen or sulphur is a heterocyclic group having 5, 6 or 7 ring atoms of which one, two, three or four, are hetero atoms selected from nitrogen, oxygen and sulphur. It is especially preferred that the heterocyclic group is thiadiazolyl, pyrazolyl, tetrazolyl or isoxazolyl, optionally substituted by one or more of G-C -alkyl, G-C -alkoxy and G-C ⁇ -cycloalkyl.
  • R 2 and R 3 together with the nitrogen atom to which they are attached as a heterocyclic group may be, for example, a group having a 5- or 6-membered ring of which one, two or three are heteroatoms, optionally fused to a benzene ring, such as thiadiazolyl, pyrazolyl, tetrazolyl, piperidinyl, piperazinyl, morpholino, or benzopiperidinyl, optionally substituted by one or more substituents including G-Cs-alkyl, G-G-alkoxy, G-Go-cycloalkyl and halogen.
  • a group having a 5- or 6-membered ring of which one, two or three are heteroatoms optionally fused to a benzene ring, such as thiadiazolyl, pyrazolyl, tetrazolyl, piperidinyl, piperazinyl, morpholino, or benzopiperidinyl, optionally substitute
  • R 1 as optionally substituted G-Cs-alkyl is preferably optionally substituted G-C 4 -alkyl, especially G-C -alkyl or substituted methyl or ethyl.
  • R 1 is substituted by a cyclic organic group, the latter may be a carbocyclic or heterocyclic group, for example a C3-Ci5-carbocyclic group or a 5- to 7-membered heterocyclic group having one or more, preferably one, two or three, ring hetero atoms selected from nitrogen, oxygen and sulfur.
  • the G-Ci5-carbocyclic group may be, for example, a cycloaliphatic group having 3 to 8 carbon atoms, preferably a G-G-cycloalkyl such as cyclopentyl, methylcyclopentyl or cyclohexyl.
  • the C 3 -Ci5-carbocyclic group may alternatively be, for example, a G-Gs aromatic group, such as phenyl, which is unsubstituted or substituted by G-Cs-alkyl, G-Q-alkoxy, halogen, cyano, -CON(R 4 )R 5 , -SO 2 N(R 4 )R 5 or G-Cs-alkylsulfonylamino where R 4 and R 5 are as hereinbefore defined.
  • the heterocyclic group may have one nitrogen, oxygen or sulfur atom in the ring or it may have two nitrogens, or one oxygen and one or two nitrogens, or one sulfur and one or two nitrogens in the ring.
  • the heterocyclic group is preferably a heterocyclic aromatic group, especially a 5- or 6- membered heterocyclic group such as furyl, imidazolyl, thiazolyl or pyridyl.
  • Preferred embodiments include those in which R 1 is hydrogen or G-C 4 -aIkyl substituted by hydroxy or G-Q-alkoxy.
  • the compounds represented by formula la or lb are capable of forming acid addition salts, particularly pharmaceutically acceptable acid addition salts.
  • Pharmaceutically acceptable acid addition salts of the compounds of formula la or lb include those of inorganic acids, for example, hydrohalic acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid; and organic acids, for example aliphatic monocarboxylic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid and butyric acid, aliphatic hydroxy acids such as lactic acid, citric acid, tartaric acid or malic acid, dicarboxylic acids such as maleic acid or succinic acid, aromatic carboxylic acids such as benzoic acid, p-chlorobenzoic acid, diphenylacetic acid or triphenylacetic acid, aromatic hydroxy acids such as o-hydroxybenzoic acid, p-hydroxybenzoic acid, 1-
  • Compounds of formula la or lb which contain acidic, e.g. carboxyl, groups, are also capable of forming salts with bases, in particular pharmaceutically acceptable bases such as those well known in the art; suitable such salts include metal salts, particularly alkali metal or alkaline earth metal salts such as sodium, potassium, magnesium or calcium salts, or salts with ammonia or pharmaceutically acceptable organic amines or heterocyclic bases such as ethanolamines, benzylamines or pyridine. These salts may be prepared from compounds of formula la or lb by known salt-forming procedures.
  • R 1 is other than hydrogen
  • the carbon atom to which R 1 is attached in formula la is asymmetric, in which case the compounds exist in individual optically active isomeric forms or as mixtures thereof, e.g. as racemic or diastereomeric mixtures.
  • the sulfur atom is asymmetric, so again the compounds exist in individual optically active isomeric forms or as mixtures thereof, e.g. as racemic or diastereomeric mixtures.
  • the invention embraces both individual optically active R and S isomers as well as mixtures, e.g. racemic or diastereomeric mixtures, thereof.
  • the invention also provides a process for the preparation of compounds of formulae la or lb which comprises
  • R 2 and R 3 are as hereinbefore defined;
  • Process variant (A) may be effected using known procedures for reaction of amines with isocyanates or analogously e.g. as hereinafter described in the Examples.
  • the reaction is conveniently carried out in an organic solvent, for example a halohydrocarbon such as dichloromethane (DCM) or an ether such as dioxane.
  • the reaction temperature may be e.g. from 0 °C to 100 °C, conveniently ambient temperature.
  • Process variant (B) may be effected using known procedures for reaction of amines with carbamic acid phenyl esters or analogously e.g. as hereinafter described in the Examples.
  • the reaction is conveniently carried out in an organic solvent such as dimethyl sulf oxide (DMSO).
  • DMSO dimethyl sulf oxide
  • the reaction temperature may be e.g. from 20 to 100 °C, conveniently ambient temperature.
  • Process variant (C) may be effected using known procedures for oxidising sulfanyl groups to form sulfonyl groups or analogously e.g. as hereinafter described in the Examples.
  • the oxidising agent used is preferably a perbenzoic acid, especially meta chloro-per-benzoic acid.
  • the reaction is conveniently carried out in an organic solvent such as dichloromethane (DCM).
  • DCM dichloromethane
  • the reaction temperature may be e.g. from 5 to 25 °C, preferably about 15 °C.
  • Process variant (D) may be effected using known procedures for reaction of amines with carbamic acid phenyl esters or analogously e.g. as hereinafter described in the Examples.
  • the reaction is conveniently carried out in an organic solvent such as dimethyl sulfoxide (DMSO).
  • DMSO dimethyl sulfoxide
  • the reaction temperature may be e.g. from 20 to 100 °C, conveniently ambient temperature.
  • Process variant (E) may be effected using known procedures for reaction of amines with isocyanates or analogously e.g. as hereinafter described in the Examples.
  • the reaction is conveniently carried out in an organic solvent, for example a halohydrocarbon such as dichloromethane (DCM) or an ether such as dioxane.
  • the reaction temperature may be e.g. from 0 °C to 100 °C, conveniently ambient temperature.
  • Process variant (F) may be effected using known procedures for oxidising sulfanyl groups to form sulfonyl groups or analogously e.g. as hereinafter described in the Examples.
  • the oxidising agent used is preferably a perbenzoic acid, especially meta chloro-per-benzoic acid.
  • the reaction is conveniently carried out in an organic solvent such as dichloromethane (DCM).
  • the reaction temperature may be e.g. from 5 to 25 °C, preferably about 15 °C.
  • Compounds of formula Ila may be prepared by reacting a compound of formula VI where Ar and X 1 are as hereinbefore defined, with a compound of formula VII
  • L is a halogen, preferably bromine or iodo
  • R 1 and m are as hereinbefore defined, with the proviso that when R 1 contains a reactive functional group such as a hydroxy group, the reactive group may be in protected form, for example a hydroxy group protected as a tert- butoxy group
  • R 9 is hydrogen or an amine-protective group, for example a tert-butoxy- carbonyl group
  • R 9 is a protective group, replacing R 9 in the product by hydrogen
  • R 1 in the product contains a protected functional group, replacing the protecting group with hydrogen, or analogously e.g. as hereinafter described in the Examples.
  • reaction between a compound of formula VH and a salt of a compound of formula VI may be effected by the procedures described in US patent US 4559349.
  • R 9 is a protective group
  • reaction between compounds of formulae VI and VII may be effected using known methods, for example in the presence of a tertiary organic base such as triethylamine or l,8-diaza-bicyclo-[5.4.0]undec-7-ene (DBU), conveniently in an inert organic solvent, for example a polar solvent such as dimethylformamide, the reaction temperature suitably being from 0 to 40°C, preferably ambient temperature.
  • a tertiary organic base such as triethylamine or l,8-diaza-bicyclo-[5.4.0]undec-7-ene (DBU)
  • an inert organic solvent for example a polar solvent such as dimethylformamide
  • Replacement of a protective group R 9 by hydrogen may be effected using known procedures; for example, where R 9 is tert-butoxy- carbonyl, by treatment with a carboxylic acid such as trifluoroacetic acid.
  • Replacement of a protecting group in R 1 may be affected using known procedures, for example, when R 1 contains a hydroxy group protected as an ether group, such as tert-butoxy, by treatment with HBr in a carboxylic acid such as acetic acid; when R 9 is a protective group, this treatment also replaces R 9 by hydrogen.
  • Compounds of formula lib where X 2 is -O- or -CH 2 - may be prepared by reacting a compound of formula V ⁇ l where Ar and X 2 are as hereinbefore defined, with a compound of formula IX where Q are as hereinbefore defined, n is 0, 1, 2 or 3 and R 9 is hydrogen or an amine- protective group, for example a tert-butoxycarbonyl group, and reducing the resulting compound to convert the carbonyl group to -C(H)-, where R 9 is a protective group, replacing R 9 in the product by hydrogen, or analogously e.g. as hereinafter described in the Examples.
  • reaction between a compound of formula IX and a salt of a compound of formula VIII may be effected by the procedures described in US patent 4559349.
  • R 9 is a protective group
  • reaction between compounds of formulae VIII and IX may be effected using known methods, for example in the presence of a tertiary organic base such as triethylamine or l,8-diaza-bicyclo[5.4.0]undec-7-ene (DBU), conveniently in an inert organic solvent, for example a polar solvent such as dimethyl-formamide, the reaction temperature suitably being from 0 to 40°C, preferably ambient temperature.
  • a tertiary organic base such as triethylamine or l,8-diaza-bicyclo[5.4.0]undec-7-ene (DBU)
  • an inert organic solvent for example a polar solvent such as dimethyl-formamide
  • the reaction temperature suitably being from 0 to 40°C, preferably ambient temperature.
  • the reduction can be carried out using a reducing agent such as LiAlH in an organic solvent such as tetrahydrofuran (THF).
  • a reducing agent such as LiAlH in an organic solvent such as tetrahydrofuran (THF).
  • Replacement of a protective group R 9 by hydrogen may be effected using known procedures; for example, where R 9 is tert-butoxy-carbonyl, by treatment with a carboxylic acid such as trifluoroacetic acid.
  • Replacement of a protecting group in R 1 may be affected using known procedures, for example, when R 1 contains a hydroxy group protected as an ether group, such as tert-butoxy, by treatment with HBr in a carboxylic acid such as acetic acid; when R 9 is a protective group, this treatment also replaces R 9 by hydrogen.
  • L is a halogen, preferably bromine or iodo, m and Q are as hereinbefore defined, and R 9 is hydrogen or an amine-protective group, for example a tert-butoxycarbonyl group, and, where R 9 is a protective group, replacing R 9 in the product by hydrogen, or analogously e.g. as hereinafter described in the Examples.
  • R 9 is hydrogen
  • reaction between a compound of formula X and a salt of a compound of formula VHI may be effected by the procedures described in US patent 4559349.
  • reaction between compounds of formulae VIII and X may be effected using known methods, for example in the presence of a tertiary organic base such as triethylamine or l,8-diazabicyclo-[5.4.0]-undec-7-ene (DBU), conveniently in an inert organic solvent, for example a polar solvent such as dimethylformamide, the reaction temperature suitably being from 0 to 40°C, preferably ambient temperature.
  • a protective group R 9 by hydrogen may be effected using known procedures; for example, where R 9 is tert-butoxy-carbonyl, by treatment with a carboxylic acid such as trifluoroacetic acid.
  • R 1 Replacement of a protecting group in R 1 may be affected using known procedures, for example, when R 1 contains a hydroxy group protected as an ether group, such as tert-butoxy, by treatment with HBr in a carboxylic acid such as acetic acid; when R 9 is a protective group, this treatment also replaces R 9 by hydrogen.
  • reaction in the presence of sodium hydride where R 10 is a protecting group, and replacing R 10 in the product by hydrogen, or analogously e.g. as hereinafter described in the Examples.
  • the reaction may be carried out in an inert organic solvent such as dimethylformamide (DMF). Suitable reaction temperatures may be from 20°C to 150°C, conveniently from 50 to 70°C.
  • the replacement of R 10 by hydrogen may be effected using known procedures or analogously e.g. as hereinafter described in the Examples.
  • the reaction is conveniently carried out in an organic solvent such as dichloromethane (DCM).
  • DCM dichloromethane
  • the reaction temperature may be e.g. from 5 to 25 °C, preferably about 15 °C.
  • the reaction is conveniently carried out in an organic solvent such as dichloromethane (DCM).
  • DCM dichloromethane
  • the reaction temperature may be e.g. from 5 to 25 °C, preferably about 15 °C.
  • Reaction of compounds of formulae X ⁇ i/XIV and XV may be effected in an inert organic solvent, e.g. an ether such as THF and/or diethyl ether; suitable reaction temperatures may be from -10°C to 10°C, conveniently from -5 to 5°C.
  • Reaction of R 11 in the product by hydrogen may be effected using known procedures or analogously e.g. as hereinafter described in the Examples.
  • R 12 is a protecting group
  • R 12 in the product by hydrogen or analogously e.g. as hereinafter described in the Examples.
  • the reaction may be carried out in an inert organic solvent such as DMF. Suitable reaction temperatures may be from 20°C to 150°C, conveniently from 50 to 70°C.
  • the replacement of R 12 by hydrogen may be effected using known procedures or analogously e.g. as hereinafter described in the Examples.
  • Compounds of formula V ⁇ l where X 2 is -S- may be prepared by reacting a compound of formula XVII Ar— SH XVII where Ar is as hereinbefore defined, with a compound of formula XVHI XVIII in the presence of sodium hydride where R 13 is a protecting group, and replacing R 13 in the product by hydrogen, or analogously e.g. as hereinafter described in the Examples.
  • the reaction may be carried out in an inert organic solvent such as dimethylformamide (DMF). Suitable reaction temperatures may be from 20°C to 150°C, conveniently from 50 to 70°C.
  • the replacement of R 13 by hydrogen may be effected using known procedures or analogously e.g. as hereinafter described in the Examples.
  • the reaction is conveniently carried out in an organic solvent such as dichloromethane (DCM).
  • DCM dichloromethane
  • the reaction temperature may be e.g. from 5 to 25 °C, preferably about 15 °C.
  • the reaction is conveniently carried out in an organic solvent such as dichloromethane (DCM).
  • DCM dichloromethane
  • the reaction temperature may be e.g. from 5 to 25 °C, preferably about 15 °C.
  • R 11 is as hereinbefore defined, with O,N-dimethylhydroxylamine hydrochloride in the presence of a peptide coupling agent such as di-imidazol-1-yl-methanone, conveniently in an inert organic solvent such as THF, suitably at reflux temperature, or analogously e.g. as hereinafter described in the Examples.
  • a peptide coupling agent such as di-imidazol-1-yl-methanone
  • the protecting groups may be chosen in accordance with the nature of the functional group, for example as described in Protective Groups in Organic Synthesis, T. W. Greene, P.G.M. Wuts, John Wiley &c Sons Inc, Third Edition, 1999, which reference also describes procedures suitable for replacement of the protecting groups by hydrogen.
  • Compounds of formula la or lb in free form may be converted into salt form, and vice versa, in a conventional manner.
  • the compounds in free or salt form can be obtained in the form of hydrates or solvates containing a solvent used for crystallization.
  • Compounds of formula la or lb can be recovered from reaction mixtures and purified in a conventional manner.
  • Isomers, such as enantiomers may be obtained in a conventional manner, e.g. by fractional crystallization or asymmetric synthesis from correspondingly asymmetrically substituted, e.g. optically active, starting materials.
  • agents of the invention are useful as pharmaceuticals. Accordingly the invention also provides a compound of formula la or lb in free or pharmaceutically acceptable salt form for use as a pharmaceutical.
  • the agents of the invention act as CCR-3 receptor antagonists, thereby inhibiting the infiltration and activation of inflammatory cells, particularly eosinophils, and inhibiting allergic response.
  • the inhibitory properties of agents of the invention can be demonstrated in the following assay:
  • the effect of agents of the invention on the binding of human eotaxin to human CCR-3 is determined.
  • Recombinant cells expressing human CCR-3 are captured by wheatgerm agglutinin (WGA) polyvinyltoluidene (PVT) SPA beads (available from Amersham), through a specific interaction between the WGA and carbohydrate residues of glycoproteins on the surface of the cells.
  • WGA wheatgerm agglutinin
  • PVT polyvinyltoluidene
  • SPA beads available from Amersham
  • Emitted a- particles from the [ 125 I]-human eotaxin excite, by its proximity, the fluorophore in the beads and produce light.
  • Free [ 125 I]-human eotaxin in solution is not in close proximity to the scintillant and hence does not produce light.
  • the scintillation count is therefore a measure of the extent to which the test compound inhibits binding of the eotaxin to the CCR-3.
  • Tris-base (2.42 g) is dissolved in distilled water, the pH of the solution is adjusted to 7.6 with hydrochloric acid and the solution is diluted with distilled water to a final volume of 1 1. The resulting buffer is stored at 4°C. A CompleteTM protease inhibitor cocktail tablet is added per 50 ml of the buffer on the day of use.
  • Confluent rat basophil leukaemia (RBL-2H3) cells stably expressing CCR3 are removed from tissue culture flasks using enzyme-free cell dissociation buffer and resuspended in phosphate-buffered saline.
  • the cells are centrifuged (800 g, 5 minutes), the pellet resuspended in ice-cold homogenisation buffer using 1 ml homogenisation buffer per gram of cells and incubated on ice for 30 minutes.
  • the cells are homogenised on ice with 10 strokes in a glass mortar and pestle.
  • the homogenate is centrifuged (800 g, 5 minutes, 4°C), the supernatant further centrifuged (48,000 g, 30 minutes, 4°C) and the pellet redissolved in Homogenisation Buffer containing 10% (v/v) glycerol.
  • the protein content of the membrane preparation is estimated by the method of Bradford (Anal. Biochem. (1976) 72:248) and aliquots are snap frozen and stored at -80°C.
  • the assay is performed in a final volume of 250 ul per well of an OptiplateTM microplate (ex Canberra Packard).
  • To selected wells of the microplate are added 50 ⁇ l of solutions of a test compound in Assay Buffer containing 5 % DMSO (concentrations from 0.01 nM to 10 ⁇ M).
  • To determine total binding 50 ⁇ l of the Assay Buffer containing 5 % DMSO is added to other selected wells.
  • 50 ⁇ l of 100 nM human eotaxin (ex R&D Systems) in Assay Buffer containing 5 % DMSO is added to further selected wells.
  • the resulting scintillations are counted using a Canberra Packard TopCountTM scintillation counter, each well being counted for 1 minute.
  • the concentration of test compound at which 50% inhibition occurs (IGo) is determined from concentration-inhibition curves in a conventional manner.
  • the compounds of the Examples hereinbelow generally have IGo values below 1 ⁇ M in the above assay.
  • the compounds of Examples 1, 19, 25, 31, 73, 94 and 131 have IGo values of 0.278, 0.002, 0.820, 0.117, 0.136, 0.124 and 0.096 ⁇ M respectively.
  • inhibitory properties of agents of the invention on binding of the alpha-1 adrenergic receptor can be determined in the following assay:
  • Cerebral cortices from male Sprague-Dawley rats (175-200 g) are dissected and homogenised in 10 volumes of ice cold 0.32 M sucrose (containing 1 mM MgCl 2 dihydrate and ImM K 2 HPO ) with a glass/Teflon homogeniser.
  • the membranes are centrifuged at 1000 x g for 15 miN, the pellet discarded and the centrifugation repeated.
  • the supernatants are pooled and centrifuged at 18,000 x g for 15 minutes.
  • the pellet is osmotically shocked in 10 volumes of water and kept on ice for 30 minutes.
  • the suspension is centrifuged at 39,000 x g for 20 minutes, resuspended in Krebs-Henseleit buffer pH 7.4 (1.17 mM MgS0 anhydrous, 4.69 mM KG, 0.7 mM K2HPO4 anhydrous, 0.11 M NaCl, 11 mM D-glucose and 25 mM NaHCO 3 ) containing 20 mM Tris, and kept for 2 days at -20°C.
  • the membranes are then thawed at 20- 23°C, washed three times with Krebs-Henseleit buffer by centrifugation at 18,000 x g for 15 minutes, left overnight at 4°C and washed again three times.
  • the final pellet is resuspended with a glass/Teflon homogeniser in 125 ml/100 membranes in the same buffer.
  • a sample is taken to determine the protein concentration (using the Bradford Assay with gamma globulin as the standard) and the remainder aliquoted and stored at -80°C.
  • the resulting membranes are subjected to a radioligand binding assay.
  • the assay is conducted in triplicate using 96 well plates containing [ 125 I]-HEAT (Amersham) (40 pM, ICj: 58.9 ⁇ 18.7 pM), unlabelled test compound and membrane (57.1 ⁇ g/ml) to yield a final volume of 250 ⁇ l (assay buffer containing 50 mM Tris-base and 0.9% (w/v) NaCl, pH 7.4).
  • the plates are incubated at 37°C for 60 minutes, after which rapid vacuum filtration over WhatmanTM GF/C 96 well filter plates is carried out.
  • Each plate is then washed three times with 10ml of ice cold assay buffer using a Brandel Cell harvester (Gaithersburg, MD). Following drying of the plates for 3 h. at 50°C, 40 ⁇ l of Microscint 20 is added to each well, the plates incubated at room temperature for a further 20 minutes and the retained radioactivity quantified in a Packard TopCount NXTTM scintillation counter.
  • test compounds Stock solutions of test compounds are dissolved initially in 100 % DMSO and diluted with assay buffer to the required concentrations to yield 1 % (v/v) DMSO.
  • concentration of test compound at which 50% inhibition occurs is determined from concentration- inhibition curves in a conventional manner.
  • agents of the invention are useful in the treatment of conditions mediated by CCR-3, particularly inflammatory or allergic conditions. Treatment in accordance with the invention may be symptomatic or prophylactic.
  • agents of the invention are useful in the treatment of inflammatory or obstructive airways diseases, resulting, for example, in reduction of tissue damage, bronchial hyper- reactivity, remodelling or disease progression.
  • Inflammatory or obstructive airways diseases to which the present invention is applicable include asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise-induced asthma, occupational asthma and asthma induced following bacterial or viral infection.
  • Treatment of asthma is also to be understood as embracing treatment of subjects, e.g.
  • Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g. of acute asthmatic or bronchoconstrictor attack, improvement in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, i.e. therapy for or intended to restrict or abort symptomatic attack when it occurs, for example anti-inflammatory (e.g. cortico- steroid) or bronchodilatory.
  • Prophylactic benefit in asthma may in particular be apparent in subjects prone to "morning dipping". "Morning dipping" is a recognised asthmatic syndrome, common to a substantial percentage of asthmatics and characterised by asthma attack, e.g. between the hours of about 4 to 6 am, i.e. at a time normally substantially distant form any previously administered symptomatic asthma therapy.
  • inflammatory or obstructive airways diseases and conditions to which the present invention is applicable include acute lung injury (ALI), acute/adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD, CO AD or COLD), including chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular other inhaled drug therapy.
  • the invention is also applicable to the treatment of bronchitis of whatever type or genesis including, e.g., acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis.
  • pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • aluminosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • aluminosis anthracosis
  • asbestosis chalicosis
  • ptilosis ptilosis
  • siderosis silicosis
  • silicosis tabacosis and byssinosis.
  • agents of the invention are also useful in the treatment of eosinophil related disorders, e.g.
  • eosinophilia in particular eosinophil related disorders of the airways (e.g. involving morbid eosinophilic infiltration of pulmonary tissues) including hyper- eosinophilia as it effects the airways and/or lungs as well as, for example, eosinophil-related disorders of the airways consequential or concomitant to Loffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma and eosinophil-related disorders affecting the airways occasioned by drug-reaction.
  • eosinophil related disorders of the airways e.g. involving morbid eosinophilic infiltration of pulmonary tissues
  • hyper- eosinophilia as it effects the air
  • Agents of the invention are also useful in the treatment of inflammatory or allergic conditions of the skin, for example psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis bullosa acquisita, and other inflammatory or allergic conditions of the skin.
  • Agents of the invention may also be used for the treatment of other diseases or conditions, in particular diseases or conditions having an inflammatory component, for example, treatment of diseases and conditions of the eye such as conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, diseases affecting the nose including allergic rhinitis, e.g.
  • atrophic, chronic, or seasonal rhinitis inflammatory conditions of the gastrointestinal tract, for example inflammatory bowel disease such as ulcerative colitis and Crohn's disease, diseases of the boneand joints including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and systemic sclerosis, and other diseases such as cyctic fibrosis, pulmonary hypertension, atherosclerosis, multiple sclerosis, diabetes (type I), myasthenia gravis, hyper IgE syndrome and acute and chronic allograft rejection, e.g. following transplantation of heart, kidney, liver, lung or bone marrow.
  • inflammatory bowel disease such as ulcerative colitis and Crohn's disease
  • diseases of the boneand joints including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and systemic sclerosis
  • other diseases such as cyctic fibrosis, pulmonary hypertension, atherosclerosis, multiple sclerosis,
  • an agent of the invention in inhibiting inflammatory conditions, for example in inflammatory airways diseases, may be demonstrated in an animal model, e.g. a mouse or rat model, of airways inflammation or other inflammatory conditions, for example as described by Szarka et al,/. Immunol. Methods (1997) 202:49-57; Renzi et al, Am. Rev. Respir. Dis. (1993) 148:932-939; Tsuyuki et al. . Clin. Invest. (1995) 96:2924-2931; and Cernadas et al (1999) Am. J. Respir. Cell Mol. Biol. 20:1-8.
  • the agents of the invention are also useful as co-therapeutic agents for use in combination with other drug substances such as anti-inflammatory, bronchodilatory, antihistamine or anti- tussive drug substances, particularly in the treatment of obstructive or inflammatory airways diseases such as those mentioned hereinbefore, for example as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs.
  • An agent of the invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance.
  • Such anti-inflammatory drugs include steroids, in particular gluco-corticosteroids such as budesonide, beclamethasone, fluticasone, ciclesonide or mometasone, or steroids described in WO 02/88167, WO 02/12266, WO 02/100879, WO 04/039827 or WO 02/00679, especially those of Examples 3, 11, 14, 17, 19, 26, 34, 37, 39, 51, 60, 67, 72, 73, 90, 99 and 101; LTB4 antagonists such as those described in US 5451700, also LY293111, CGS025019C, CP- 195543, SC-53228, BILL 284, ONO 4057 and SB 209247; LTD4 antagonists such as montelukast and zafirlukast; Dopamine receptor agonists such as cabergoline, bromocriptine, ropinirole and 4-hydroxy-7- [2- [ [2- [2- [ [3 - (2-phenylethoxy)
  • Such bronchodilatory drugs include anticholinergic or antimuscarinic agents, in particular ipratropium bromide, oxitropium bromide, tiotropium bromide, CHF 4226 (Chiesi) and glycopyrrolate, but also those described in WO 01/04118, WO 02/51841, WO 02/53564, WO 03/00840, WO 03/87094, WO 04/05285, WO 02/00652, WO 03/53966, EP 424021, US 5171744, US 3714357, US 5171744, WO 03/33495 and WO 04/018422; and beta ( ⁇ )-2- adrenoceptor agonists such as albuterol (salbutamol), metaproterenol, terbutaline, salmeterol, fenoterol, procaterol, and especially, formoterol and pharmaceutically acceptable salts thereof, and compounds (in free or salt or solvate form) of formula (I) of WO 00
  • ⁇ -2-adrenoreceptor agonists include compounds such as those described in JP 05025045, US 2002/0055651, WO 93/18007, WO 99/64035, WO 01/42193, WO 01/83462, WO 02/066422, WO 02/070490, WO 02/076933, WO 03/24439, WO 03/72539, WO 03/42160, WO 03/91204, WO 03/42164, WO 03/99764, WO 04/11416, WO 04/16578, WO 04/22547, WO 04/32921, WO 04/33412, WO 04/37773, WO 04/37807, WO 04/39762, WO 04/39766, WO 04/45618 and WO 04/46083.
  • Such co-therapeutic antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine as well as those disclosed in JP 2004107299, WO 03/99807 and WO 04/26841.
  • Combinations of agents of the invention and one or more steroids, beta-2 agonists, PDE4 inhibitors or LTD4 antagonists may be used, for example, in the treatment of COPD or, particularly, asthma.
  • Combinations of agents of the invention and anticholinergic or antimuscarinic agents, PDE4 inhibitors, dopamine receptor agonists or LTB4 antagonists may be used, for example, in the treatment of asthma or, particularly, COPD.
  • Other useful combinations of agents of the invention with anti-inflammatory drugs are those with other antagonists of chemokine receptors, e.g.
  • TAK-770 N
  • the invention also provides a method for the treatment of a condition mediated by CCR-3, for example an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease, which comprises administering to a subject, particularly a human subject, in need thereof an effective amount of a compound of formula la or lb in a free or pharmaceutically acceptable salt form as hereinbefore described.
  • the invention provides the use of a compound of formula la or lb, in free or pharmaceutically acceptable salt form, as hereinbefore described for the manufacture of a medicament for the treatment of a condition mediated by CCR-3, e.g. an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease.
  • the agents of the invention may be administered by any appropriate route, e.g. orally, for example in the form of a tablet or capsule; parenterally, for example intravenously; by inhalation, for example in the treatment of inflammatory or obstructive airways disease; intranasally, for example in the treatment of allergic rhinitis; topically to the skin, e.g. in the treatment of atopic dermatitis; or rectally, e.g. in the treatment of inflammatory bowel disease.
  • any appropriate route e.g. orally, for example in the form of a tablet or capsule; parenterally, for example intravenously; by inhalation, for example in the treatment of inflammatory or obstructive airways disease; intranasally, for example in the treatment of allergic rhinitis; topically to the skin, e.g. in the treatment of atopic dermatitis; or rectally, e.g. in the treatment of inflammatory bowel disease.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising as active ingredient a compound of formula la or lb in free or pharmaceutically acceptable salt form, optionally together with a pharmaceutically acceptable diluent or carrier therefor.
  • the composition may contain a co-therapeutic agent such as an anti-inflammatory bronchodilatory or antihistamine drug as hereinbefore described.
  • Such compositions may be prepared using conventional diluents or excipients and techniques known in the galenic art.
  • oral dosage forms may include tablets and capsules.
  • Formulations for topical administration may take the form of creams, ointments, gels or transdermal delivery systems, e.g. patches.
  • Compositions for inhalation may comprise aerosol or other atomizable formulations or dry powder formulations.
  • the composition comprises an aerosol formulation
  • it preferably contains, for example, a hydro-fluoro-alkane (HFA) propellant such as HFA134a or HFA227 or a mixture of these, and may contain one or more co-solvents known in the art such as ethanol (up to 20% by weight), and/or one or more surfactants such as oleic acid or sorbitan trioleate, and/or one or more bulking agents such as lactose.
  • HFA hydro-fluoro-alkane
  • the composition comprises a dry powder formulation, it preferably contains, for example, the compound of formula la or lb having a particle diameter up to 10 microns, optionally together with a diluent or carrier, such as lactose, of the desired particle size distribution and a compound that helps to protect against product performance deterioration due to moisture e.g. magnesium stearate.
  • a diluent or carrier such as lactose
  • the composition comprises a nebulised formulation, it preferably contains, for example, the compound of formula la or lb either dissolved, or suspended, in a vehicle containing water, a co-solvent such as ethanol or propylene glycol and a stabiliser, which may be a surfactant.
  • the invention includes (A) an agent of the invention in inhalable form, e.g. in an aerosol or other atomisable composition or in inhalable particulate, e.g. micronised form, (B) an inhalable medicament comprising an agent of the invention in inhalable form; (C) a pharmaceutical product comprising such an agent of the invention in inhalable form in association with an inhalation device; and (D) an inhalation device containing an agent of the invention in inhalable form.
  • A an agent of the invention in inhalable form, e.g. in an aerosol or other atomisable composition or in inhalable particulate, e.g. micronised form
  • B an inhalable medicament comprising an agent of the invention in inhalable form
  • C a pharmaceutical product comprising such an agent of the invention in inhalable form in association with an inhalation device
  • an inhalation device containing an agent of the invention in inhalable form.
  • Dosages of agents of the invention employed in practising the present invention will of course vary depending, for example, on the particular condition to be treated, the effect desired and the mode of administration.
  • suitable daily dosages for administration by inhalation are of the order of 0.01 to 30 mg/kg while for oral administration suitable daily doses are of the order of 0.01 to 100 mg/kg.
  • reaction mixture is then treated with a solution of [(S)-l-(tert-butyl-diphenyl-silanyloxymethyl)-3-hydroxy-propyl]-carbamic acid tert-butyl ester (1.24 g, 2.8 mmol) in dichloromethane (5 ml).
  • dichloromethane 5 ml
  • the reaction mixture is refluxed for 2 hours under argon, then filtered through a CeliteTM filter pad, washing with dichloromethane.
  • the filtrate is washed with 5% aqueous sodium thiosulphate solution and water, dried over MgSO 4 and evaporated.
  • Te solvent is evaporated and the crude product is purified by flash silica chromatography (elution with dichloromethane: methanol, 99:1 to 95:5 ) to afford l- ⁇ (S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-l-yl]-l-hydroxymethyl-propyl ⁇ -3-(3,5- dimethoxy-phenyl)-urea [MH]+ 484.32
  • Examples 7 to 12 The compounds of these Examples are prepared in a manner that is analogous to that described in Examples 1 to 6 but using ((S)-3-Iodo-l-methoxymethyl-propyl)-carbamic acid tert-butyl ester in place of [(S)-l-(tert-butyl-diphenyl-silanyloxymethyl)-3-iodo-propyl]- carbamic acid tert-butyl ester.
  • the compounds of these Examples are prepared in a manner that is analogous to that described in Examples 1 to 6 but using ((R)-3-iodo-l-methyl-propyl)-carbamic acid tert-butyl ester in place of [(S)-l-(tert-butyl-diphenyl-silanyloxymethyl)-3-iodo-propyl]-carbamic acid tert-butyl ester.
  • the crude product is purified by flash silica chromatography (elution with iso-hexane: ether, 8:2 ) to afford l-Benzhydryl-3-(4-chloro-phenylsulfanyl)-azetidine as a pale yellow solid.
  • Azetidin-3-yl-(4-chloro-benzoyl)-methanone hydrochloride and all other substituted benzoyl azetidine compounds are made analogously.
  • reaction mixture is quenched with saturated sodium sulphate solution and filtered through a CeliteTM filter pad washing through with ethylacetate. The filtrate is dried over magnesium sulphate and evaporated.
  • the crude product is purified by flash chromatography (eluant gradient dichloromethane:methanol 1:0 to 9:1) to afford (l- ⁇ 2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]- ethyl ⁇ -cyclobutyl)-carbamic acid tert-butyl ester. [MH]+ 381.20.
  • reaction mixture is quenched with saturated sodium sulphate solution and filtered through a CeliteTM filter pad washing through with ethyl acetate. The filtrate is dried over magnesium sulphate and evaporated.
  • the crude product is purified by flash chromatography (eluant gradient dichloromethane:methanol 9:1 to 9:3) to afford as a 1:1 mixture of 3-[3-(4-Chloro-phenoxy)- azetidin-l-yl]-l,l-dimethyl-propylamine. [MH]+ 269.1 and ⁇ 3-[3-(4-Chloro-phenoxy)-azetidin- l-yl]-l,l-dimethyl-propyl ⁇ -methyl-amine [MH]+ 283.12.
  • the compounds of these Examples are trans analogues of the compounds of Examples 31 to 51 respectively. They are prepared analogously but using the intermediate BOC-trans-2-amino- cyclohexylcarboxylic acid instead of BOC-cis-2-amino-cyclohexylcarboxylic acid.
  • Examples 101 to 114 The compounds of these Examples are prepared using procedures that are analogous to those used to prepare the compounds of Examples 94 to 100 but using the appropriate amine.
  • the compounds of these Examples are prepared using procedures that are analogous to those used to prepare the compounds of Examples 31 to 37 and 52 to 58 respectively but using the appropriate starting materials.
  • the compounds of these Examples are prepared using procedures that are analogous to those used to prepare the compounds of Examples 31 to 37 and 52 to 58 respectively but using the appropriate starting materials.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)

Abstract

Compounds of formula Ia or Ib in free or salt form, wherein Ar, X1, X2, m, R1, Q, Y, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by CCR-3, for example an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Description

1 , 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES
This invention relates to organic compounds, their preparation and their use as pharmaceuticals.
In one aspect the invention provides compounds of formula la or lb
in free or salt form, where
Ar is phenyl optionally substituted by one or more substituents selected from halogen, Ci-Cs-alkyl, cyano or nitro;
X1 is -S-, -S(=O)- or -S(=O)2-;
X2 is -C(=O)-, -O-, -CH2-, -S-, -S(=O)- or -S(=O)2-; m is 1, 2, 3 or 4;
R1 is hydrogen or Ci-Cs-alkyl optionally substituted by hydroxy, Ci-Cs-alkoxy, acyloxy, halogen, carboxy, Ci-Cs-alkoxycarbonyl, -N(R4)R5, -CON(R6)R7 or by a monovalent cyclic organic group having 3 to 15 atoms in the ring system;
Q has the formula Ra / \ C— C — where Ra is Ci-Cs-alkylene, or Q is -C(Rb)(Rc)- where Rb and Rc are independently Ci-Cg-alkyl or Rb and Rc together form a C3-Cιo-cycloalkyl; Y is oxygen or sulfur;
R2 is hydrogen, Ci-Cs-alkyl or C3-Cιo-cycloalkyl and R3 is Ci-Cs-alkyl substituted by phenyl, phenoxy, acyloxy or naphthyl, or R3 is C3-Cιo-cycloalkyl optionally having a benzo group fused thereto, a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms, phenyl or naphthyl, said phenyl, phenoxy or naphthyl groups being optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, acyl, nitro, -SO2NH2, Ci-Cs- alkyl optionally substituted by Ci-Cs-alkoxy, Ci-Cs-haloalkyl, Ci-Cs-alkoxy, Ci-Cs- haloalkoxy, Ci-Cs-alkylthio, -SO -Cι-Cs-alkyl, Ci-Cs-alkoxycarbonyl, Ci-Cs-acylamino optionally substituted on the nitrogen atom by Ci-Cs-alkyl, Ci-Cs-alkylamino, aminocarbonyl, Ci-Cδ-alkylamino-carbonyl, di(Cι-Cs-alkyl)amino, di(Cι-Cs-alkyl)aminocarbonyl, di(Cι-C8- alkyl)aminocarbonyl-methoxy, or R2 and R3 together with the nitrogen atom to which they are attached denote a heterocyclic group having 5 to 10 ring atoms of which 1, 2 or 3 are hetero atoms;
R4 and R5 are each independently hydrogen or G-Cs-alkyl, or R4 is hydrogen and R5 is hydroxy-Ci-Cs-alkyl, acyl, -SO2R8 or -CON(R6)R7, or R4 and R5 together with the nitrogen atom to which they are attached denote a 5-or 6-membered heterocyclic group;
R6 and R7 are each independently hydrogen or Ci-Cs-alkyl, or R6 and R7 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group; and
R8 is Ci-Cs-alkyl, Ci-Cs-haloalkyl, or phenyl optionally substituted by Ci-Cs-alkyl.
Terms used in the specification have the following meanings:
"Ci-Cs-alkyl" as used herein denotes straight chain or branched alkyl having 1 to 8 carbon atoms. Preferably, Ci-Cs-alkyl is Cι-C4-alkyl.
"Ci-Cs-alkylene" as used herein denotes straight chain or branched alkylene that contains 1 to 8 carbon atoms. Preferably, G-Cs-alkylene is G-C4-alkylene, especially straight chain butylene. "C3-Cιo-cycloalkyl" as used herein denotes cycloalkyl having 3 to 10 ring carbon atoms, for example a monocyclic group such as a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, any of which can be substituted by one or more, usually one or two, Cι-C -alkyl groups, or a bicyclic group such as bicycloheptyl or bicyclooctyl. Preferably C3-Cιo-cycloalkyl is C3-C6-cycloalkyl, especially cyclopropyl or cyclobutyl.
"Ci-Cs-alkoxy" as used herein denotes straight chain or branched alkoxy having 1 to 8 carbon atoms. Preferably, Ci-Cs-alkoxy is G-C -alkoxy.
"Ci-Cs-haloalkyl" as used herein denotes Ci-Cs-alkyl as hereinbefore defined substituted by one or more halogen atoms, preferably one, two or three halogen atoms.
"Ci-Cβ-haloalkoxy" as used herein denotes Cι-C8-alkoxy as hereinbefore defined substituted by one or more halogen atoms, preferably one, two or three halogen atoms.
"Aminocarbonyl" as used herein denotes amino attached through the nitrogen atom to a carbonyl group.
"Ci-Cs-alkylamino" and "di(Cι-C8-alkyl)amino" as used herein denote amino substituted respectively by one or two G-Cs-alkyl groups as hereinbefore defined, which may be the same or different. Preferably Ci-Cs-alkylamino and di(Cι-C8-alkyl)amino are respectively Cι-C - alkylamino and di(Cι-C -alkyl)amino.
" Cι-C8-alkylaminocarbonyl" and "di(Cι-Cs-alkyl)aminocarbonyl" as used herein denote aminocarbonyl as hereinbefore defined substituted respectively on the nitrogen atom by one or two Ci-Cs-alkyl groups as hereinbefore defined, which may be the same or different. Preferably Cι-C8-alkylaminocarbonyl and di(G-C8-alkyl)aminocarbonyl are respectively G-C -alkyl- aminocarbonyl and di(Cι-C -alkyl)aminocarbonyl.
" G-Cs-alkyl thio" as used herein denotes Ci-Cs-alkyl as hereinbefore defined linked to -S-.
"Acyl" as used herein denotes alkylcarbonyl, for example G-Cs-alkylcarbonyl where G-Cs- alkyl may be one of the G-Cs-alkyl groups hereinbefore mentioned, optionally substituted by one or more halogen atoms; cycloalkylcarbonyl, for example C3-C8-cycloalkylcarbonyl where C3-C8-cycloalkyl may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; 5- or 6- membered heterocyclylcarbonyl having one or two hetero atoms selected from nitrogen, oxygen and sulfur in the ring, such as furylcarbonyl or pyridylcarbonyl; arylcarbonyl, for example G-Go-arylcarbonyl such as benzoyl; or aralkylcarbonyl, for example C to Go-aryl-G-C -alkylcarbonyl such as benzylcarbonyl or phenylethylcarbonyl. Preferably acyl is G-C -alkylcarbonyl.
"Acyloxy" as used herein denotes alkylcarbonyloxy, for example G-Cs-alkylcarbonyloxy where G-Cs-alkyl may be one of the G-Cs-alkyl groups hereinbefore mentioned, optionally substituted by one or more halogen atoms; cycloalkylcarbonyloxy, for example G-Cs-cyclo- alkylcarbonyloxy where G-Cs-cycloalkyl may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; 5- or 6- membered heterocyclylcarbonyloxy having one or two hetero atoms selected from nitrogen, oxygen and sulfur in the ring, such as furylcarbonyloxy or pyridylcarbonyloxy; arylcarbonyloxy, for example C6-Go-arylcarbonyl- oxy such as benzoyloxy; or aralkylcarbonyloxy, for example to Go-aryl-G-C -alkyl- carbonyloxy such as benzylcarbonyloxy or phenylethylcarbonyloxy, or aryloxyalkylcarbonyl- oxy, for example, Cg-Go-aryloxy-Cr-Cs-alkylcarbonyloxy, any of which is optionally substituted in the aryl moiety by at least one substituent selected from G-G-alkoxy, halogen, G-Cδ-alkylcarbonyl, aminosulfonyl, G-Cs-alkylaminosulfonyl and di(G-C8-alkyl)amino- sulfonyl. Preferably acyloxy is G-C -alkylcarbonyloxy, or benzoyloxy or phenoxy-G-C - alkylcarbonyloxy. optionally substituted in the benzene ring thereof by at least one substituent selected from G-C -alkoxy, G-C4-alkylcarbonyl or aminosulfonyl.
"Acylamino" as used herein denotes amino substituted by acyl as hereinbefore defined.
"Halogen" as used herein may be fluorine, chlorine, bromine or iodine; preferably it is fluorine, chlorine or bromine.
"G-Cδ-alkoxycarbonyl" as used herein denotes G-Cs-alkoxy as hereinbefore defined attached through the oxygen atom to a carbonyl group.
"Di-(G-Cs-alkyl)aminocarbonylmethoxy" as used herein denotes aminocarbonylmethoxy disubstituted on the amino nitrogen atom by G-Cs-alkyl as hereinbefore defined, the two G-Cs-alkyl groups being the same or different. "Optionally substituted" means the group referred to can be substituted at one or more positions by any one or any combination of the radicals listed thereafter.
In Ar, the phenyl group may be substituted, for example by one, two or three, preferably one or two halogen atoms, preferably selected from fluorine and chlorine atoms, or by one or two G-Cs-alkyl, cyano or nitro groups, or by G-Cs-alkyl and one or two halogen, preferably fluorine or chlorine, atoms. When there is one halogen substituent, it is preferably para to the indicated group X1 or X2. When there are two or three halogen substituents, preferably one is para to the indicated group X1 or X2 and at least one of the others is ortho to the para-halogen substituent.
R3 as substituted phenyl may, for example, be substituted by one, two, three, four or five, preferably by one, two or three, of the abovementioned substituents. R3 may be, for example, phenyl substituted by one, two or three substituents selected from halogen, cyano, hydroxy, nitro, G-G-alkoxy, G-C -alkoxycarbonyl, G-C4-haloalkoxy, -CO-NH2, di(G-C -alkyl)- aminocarbonylmethoxy, G-C -alkyl optionally substituted by G-C -alkoxy, G-C -haloalkyl, G-C -alkylcarbonyl, G-C4-alkylthio, -SO2-NH2, -SO2-G-C4-alkyl, di(G-C4-alkyl)amino, G- C -alkylaminocarbonyl or G-C4-alkyl-carbonylamino. R3 as substituted phenyl is preferably phenyl substituted by one or more substituents selected from cyano, halogen, G-C -alkyl optionally substituted by G-C -alkoxy, G-C4-alkylcarbonyl, G-C4-alkoxy, G-C -alkoxy- carbonyl, -CO-NH2, -SO2-NH2, -SO2-G-C -alkyl, G-C4-alkyl-aminocarbonyl, di(G-C4-alkyl)- aminocarbonyl-methoxy or G-C4-alkyl-carbonylamino, especially cyanophenyl, particularly meta-cyanophenyl, and disubstituted phenyl where one substituent is G-C -alkoxy or di(G- C -alkyl)aminocarbonylmethoxy, preferably ortho to the bond linking R3 to the remainder of the molecule shown in formula la or lb, and the other, preferably para to the G-C -alkoxy group, is G-C -alkoxy, halogen, cyano or G-C4-alkyl. When R3 is G-C -alkyl substituted by optionally substituted phenoxy, the substituent(s) on phenoxy may be, for example, one, two or three substituents selected from halogen, cyano, G-Cs-alkyl, G-G-alkoxy or G-G-alkyl- carbonyl.
R3 as a heterocyclic group may be, for example, a group having 5 to 11 ring atoms of which one, two, three or four, preferably one or two, are hetero atoms selected from nitrogen, oxygen or sulfur, such as pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyranyl, pyrazinyl, or a 5-, 6- or 7-membered heterocyclic, ring preferably having one or two oxygen or nitrogen ring atoms, fused to a benzene ring, said heterocyclic group being optionally substituted by substituents including halogen, G-C4-alkyl optionally substituted by G-C -alkoxy, G-C -alkoxy, -SO2-Cι-Cs-alkyl, Q-Go-cycloalkyl, phenyl, phenyl-G-C4-alkyl and C2-C4-alkynyl. Preferably a heterocyclic group having 5 to 11 ring atoms of which one, two, three or four, preferably one or two, are hetero atoms selected from nitrogen, oxygen or sulphur is a heterocyclic group having 5, 6 or 7 ring atoms of which one, two, three or four, are hetero atoms selected from nitrogen, oxygen and sulphur. It is especially preferred that the heterocyclic group is thiadiazolyl, pyrazolyl, tetrazolyl or isoxazolyl, optionally substituted by one or more of G-C -alkyl, G-C -alkoxy and G-Cδ-cycloalkyl.
R2 and R3 together with the nitrogen atom to which they are attached as a heterocyclic group may be, for example, a group having a 5- or 6-membered ring of which one, two or three are heteroatoms, optionally fused to a benzene ring, such as thiadiazolyl, pyrazolyl, tetrazolyl, piperidinyl, piperazinyl, morpholino, or benzopiperidinyl, optionally substituted by one or more substituents including G-Cs-alkyl, G-G-alkoxy, G-Go-cycloalkyl and halogen.
R1 as optionally substituted G-Cs-alkyl is preferably optionally substituted G-C4-alkyl, especially G-C -alkyl or substituted methyl or ethyl. When R1 is substituted by a cyclic organic group, the latter may be a carbocyclic or heterocyclic group, for example a C3-Ci5-carbocyclic group or a 5- to 7-membered heterocyclic group having one or more, preferably one, two or three, ring hetero atoms selected from nitrogen, oxygen and sulfur. The G-Ci5-carbocyclic group may be, for example, a cycloaliphatic group having 3 to 8 carbon atoms, preferably a G-G-cycloalkyl such as cyclopentyl, methylcyclopentyl or cyclohexyl. The C3-Ci5-carbocyclic group may alternatively be, for example, a G-Gs aromatic group, such as phenyl, which is unsubstituted or substituted by G-Cs-alkyl, G-Q-alkoxy, halogen, cyano, -CON(R4)R5, -SO2N(R4)R5 or G-Cs-alkylsulfonylamino where R4 and R5 are as hereinbefore defined. The heterocyclic group may have one nitrogen, oxygen or sulfur atom in the ring or it may have two nitrogens, or one oxygen and one or two nitrogens, or one sulfur and one or two nitrogens in the ring. The heterocyclic group is preferably a heterocyclic aromatic group, especially a 5- or 6- membered heterocyclic group such as furyl, imidazolyl, thiazolyl or pyridyl. Preferred embodiments include those in which R1 is hydrogen or G-C4-aIkyl substituted by hydroxy or G-Q-alkoxy.
Throughout this specification and in the claims that follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
Preferred compounds of the present invention include those that are (i) compounds of formula la in free or salt form, wherein Ar is phenyl substituted by halo; X1 is -S-, -S(=O)- or -S(=O)2-; m is 2; R1 is G-G-alkyl optionally substituted by hydroxy or G-Cs-alkoxy; Y is oxygen; R2 is hydrogen; and R3 is a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms; or (ii) compounds of formula lb in free or salt form, wherein Ar is phenyl substituted by halo; X2 is -O-, -C(=O)- or -CH2-; m is 1 or 2; Q has the formula Ra / \ C— C where Ra is G-Cs-alkylene, or Q is -C(Rb)(Rc)- where Rb and Rc are independently G-Cs-alkyl or Rb and Rc together form a G-Go-cycloalkyl; R2 is hydrogen; and R3 is a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms.
Especially preferred compounds of the present invention include those that are (i) compounds of formula la in free or salt form, wherein Ar is phenyl substituted by halo, preferably chloro; X1 is -S-, -S(=O)- or -S(=O)2-; m is 2; R1 is G-C4-alkyl optionally substituted by hydroxy or G-C4-alkoxy; Y is oxygen; R2 is hydrogen; and R3 is a heterocyclic group having 5, 6 or 7 ring atoms of which one, two, three or four, are hetero atoms selected from nitrogen, oxygen and sulphur, said heterocyclic group being optionally substituted by G-C4-alky, G-C -alkoxy or G-G-cycloalkyl; or (ii) compounds of formula lb in free or salt form, wherein Ar is phenyl substituted by halo, preferably chloro; X2 is -O-, -C(=O)- or -CH2-; m is 1 or 2; Q has the formula Ra / \ C— C — where Ra is G-G-alkylene, or Q is -C(Rb)(Rc)- where Rb and Rc are independently G-C4-alkyl or Rb and Rc together form a G-G-cycloalkyl; R2 is hydrogen; and R3 is a heterocyclic group having 5, 6 or 7 ring atoms of which one, two, three or four, are hetero atoms selected from nitrogen, oxygen and sulphur, said heterocyclic group being optionally substituted by G-C4-alkyl or G-G-cycloalkyl.
The compounds represented by formula la or lb are capable of forming acid addition salts, particularly pharmaceutically acceptable acid addition salts. Pharmaceutically acceptable acid addition salts of the compounds of formula la or lb include those of inorganic acids, for example, hydrohalic acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid; and organic acids, for example aliphatic monocarboxylic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid and butyric acid, aliphatic hydroxy acids such as lactic acid, citric acid, tartaric acid or malic acid, dicarboxylic acids such as maleic acid or succinic acid, aromatic carboxylic acids such as benzoic acid, p-chlorobenzoic acid, diphenylacetic acid or triphenylacetic acid, aromatic hydroxy acids such as o-hydroxybenzoic acid, p-hydroxybenzoic acid, 1- hydroxynaphthalene-2-carboxylic acid or 3-hydroxynaphthalene-2-carboxylic acid, and sulfonic acids such as methanesulfonic acid or benzenesulfonic acid. These salts may be prepared from compounds of formula la or lb by known salt-forming procedures.
Compounds of formula la or lb which contain acidic, e.g. carboxyl, groups, are also capable of forming salts with bases, in particular pharmaceutically acceptable bases such as those well known in the art; suitable such salts include metal salts, particularly alkali metal or alkaline earth metal salts such as sodium, potassium, magnesium or calcium salts, or salts with ammonia or pharmaceutically acceptable organic amines or heterocyclic bases such as ethanolamines, benzylamines or pyridine. These salts may be prepared from compounds of formula la or lb by known salt-forming procedures.
When R1 is other than hydrogen, the carbon atom to which R1 is attached in formula la is asymmetric, in which case the compounds exist in individual optically active isomeric forms or as mixtures thereof, e.g. as racemic or diastereomeric mixtures. When X1 is -S(=O) , the sulfur atom is asymmetric, so again the compounds exist in individual optically active isomeric forms or as mixtures thereof, e.g. as racemic or diastereomeric mixtures. In both cases the invention embraces both individual optically active R and S isomers as well as mixtures, e.g. racemic or diastereomeric mixtures, thereof.
When Q has the formula Ra / \ C— C where Ra is G-G-alkylene the compounds can exist in individual optically active isomeric forms or as mixtures thereof, e.g. as racemic or diastereomeric mixtures. When X2 is -S(=O) , the sulfur atom is asymmetric, so again the compounds exist in individual optically active isomeric forms or as mixtures thereof, e.g. as racemic or diastereomeric mixtures. In both cases the invention embraces both individual optically active R and S isomers as well as mixtures, e.g. racemic or diastereomeric mixtures, thereof.
Specific especially preferred compounds of the invention are those described hereinafter in the Examples.
The invention also provides a process for the preparation of compounds of formulae la or lb which comprises
(i) (A) for the preparation of compounds of formula la where R2 is hydrogen, reacting a compound of formula Ha
or a protected form thereof, where Ar, X1, m and R1 are as hereinbefore defined, with a compound of formula III γ=C=N— R3 III where Y and R3 are as hereinbefore defined; or
(B) for the preparation of compounds of formula la where Y is oxygen, reacting a compound of formula Ila where Ar, X1, m and R1 are as hereinbefore defined, with a compound of formula IN
where R2 and R3 are as hereinbefore defined; or
(C) for the preparation of compounds of formula la where X1 is -S(=O)2-, oxidising a compound of formula la in protected form where X1 is -S- and Ar, m, R1, Y, R2 and R3 are hereinbefore defined;
(D) for the preparation of compounds of formula lb, reacting a compound of formula lib
where Ar, X2, m and Q are as hereinbefore defined, with a compound of formula IN where R2 and R3 are as hereinbefore defined;
(E) for the preparation of compounds of formula lb where R2 is hydrogen, reacting a compound of formula lib where Ar, X2, m and Q are as hereinbefore defined, with a compound of formula V 0=C=Ν— R3 V where R3 is as hereinbefore defined; or
(F) for the preparation of compounds of formula lb where X2 is -S(=O)2-, oxidising a compound of formula lb in protected form where X2 is -S- and Ar, m, Q, R2 and R3 are as hereinbefore defined; and (ii) recovering the product in free or salt form.
Process variant (A) may be effected using known procedures for reaction of amines with isocyanates or analogously e.g. as hereinafter described in the Examples. The reaction is conveniently carried out in an organic solvent, for example a halohydrocarbon such as dichloromethane (DCM) or an ether such as dioxane. The reaction temperature may be e.g. from 0 °C to 100 °C, conveniently ambient temperature.
Process variant (B) may be effected using known procedures for reaction of amines with carbamic acid phenyl esters or analogously e.g. as hereinafter described in the Examples. The reaction is conveniently carried out in an organic solvent such as dimethyl sulf oxide (DMSO). The reaction temperature may be e.g. from 20 to 100 °C, conveniently ambient temperature.
Process variant (C) may be effected using known procedures for oxidising sulfanyl groups to form sulfonyl groups or analogously e.g. as hereinafter described in the Examples. The oxidising agent used is preferably a perbenzoic acid, especially meta chloro-per-benzoic acid. The reaction is conveniently carried out in an organic solvent such as dichloromethane (DCM). The reaction temperature may be e.g. from 5 to 25 °C, preferably about 15 °C.
Process variant (D) may be effected using known procedures for reaction of amines with carbamic acid phenyl esters or analogously e.g. as hereinafter described in the Examples. The reaction is conveniently carried out in an organic solvent such as dimethyl sulfoxide (DMSO). The reaction temperature may be e.g. from 20 to 100 °C, conveniently ambient temperature.
Process variant (E) may be effected using known procedures for reaction of amines with isocyanates or analogously e.g. as hereinafter described in the Examples. The reaction is conveniently carried out in an organic solvent, for example a halohydrocarbon such as dichloromethane (DCM) or an ether such as dioxane. The reaction temperature may be e.g. from 0 °C to 100 °C, conveniently ambient temperature.
Process variant (F) may be effected using known procedures for oxidising sulfanyl groups to form sulfonyl groups or analogously e.g. as hereinafter described in the Examples. The oxidising agent used is preferably a perbenzoic acid, especially meta chloro-per-benzoic acid. The reaction is conveniently carried out in an organic solvent such as dichloromethane (DCM). The reaction temperature may be e.g. from 5 to 25 °C, preferably about 15 °C. Compounds of formula Ila may be prepared by reacting a compound of formula VI where Ar and X1 are as hereinbefore defined, with a compound of formula VII
where L is a halogen, preferably bromine or iodo, and R1 and m are as hereinbefore defined, with the proviso that when R1 contains a reactive functional group such as a hydroxy group, the reactive group may be in protected form, for example a hydroxy group protected as a tert- butoxy group, and R9 is hydrogen or an amine-protective group, for example a tert-butoxy- carbonyl group, and, where R9 is a protective group, replacing R9 in the product by hydrogen, and, where R1 in the product contains a protected functional group, replacing the protecting group with hydrogen, or analogously e.g. as hereinafter described in the Examples. When R9 is hydrogen, reaction between a compound of formula VH and a salt of a compound of formula VI may be effected by the procedures described in US patent US 4559349. When R9 is a protective group, reaction between compounds of formulae VI and VII may be effected using known methods, for example in the presence of a tertiary organic base such as triethylamine or l,8-diaza-bicyclo-[5.4.0]undec-7-ene (DBU), conveniently in an inert organic solvent, for example a polar solvent such as dimethylformamide, the reaction temperature suitably being from 0 to 40°C, preferably ambient temperature. Replacement of a protective group R9 by hydrogen may be effected using known procedures; for example, where R9 is tert-butoxy- carbonyl, by treatment with a carboxylic acid such as trifluoroacetic acid. Replacement of a protecting group in R1 may be affected using known procedures, for example, when R1 contains a hydroxy group protected as an ether group, such as tert-butoxy, by treatment with HBr in a carboxylic acid such as acetic acid; when R9 is a protective group, this treatment also replaces R9 by hydrogen.
Compounds of formula lib where X2 is -O- or -CH2- may be prepared by reacting a compound of formula Vϋl where Ar and X2 are as hereinbefore defined, with a compound of formula IX where Q are as hereinbefore defined, n is 0, 1, 2 or 3 and R9 is hydrogen or an amine- protective group, for example a tert-butoxycarbonyl group, and reducing the resulting compound to convert the carbonyl group to -C(H)-, where R9 is a protective group, replacing R9 in the product by hydrogen, or analogously e.g. as hereinafter described in the Examples. When R9 is hydrogen, reaction between a compound of formula IX and a salt of a compound of formula VIII may be effected by the procedures described in US patent 4559349. When R9 is a protective group, reaction between compounds of formulae VIII and IX may be effected using known methods, for example in the presence of a tertiary organic base such as triethylamine or l,8-diaza-bicyclo[5.4.0]undec-7-ene (DBU), conveniently in an inert organic solvent, for example a polar solvent such as dimethyl-formamide, the reaction temperature suitably being from 0 to 40°C, preferably ambient temperature. The reduction can be carried out using a reducing agent such as LiAlH in an organic solvent such as tetrahydrofuran (THF). Replacement of a protective group R9 by hydrogen may be effected using known procedures; for example, where R9 is tert-butoxy-carbonyl, by treatment with a carboxylic acid such as trifluoroacetic acid. Replacement of a protecting group in R1 may be affected using known procedures, for example, when R1 contains a hydroxy group protected as an ether group, such as tert-butoxy, by treatment with HBr in a carboxylic acid such as acetic acid; when R9 is a protective group, this treatment also replaces R9 by hydrogen.
Compounds of formula Lib where X2 is -C(=O)-, -S-, -S(=O)- or -S(=O)2- may be prepared by reacting a compound of formula VIII, where Ar and X2 are as hereinbefore defined, with a compound of formula X
where L is a halogen, preferably bromine or iodo, m and Q are as hereinbefore defined, and R9 is hydrogen or an amine-protective group, for example a tert-butoxycarbonyl group, and, where R9 is a protective group, replacing R9 in the product by hydrogen, or analogously e.g. as hereinafter described in the Examples. When R9 is hydrogen, reaction between a compound of formula X and a salt of a compound of formula VHI may be effected by the procedures described in US patent 4559349. When R9 is a protective group, reaction between compounds of formulae VIII and X may be effected using known methods, for example in the presence of a tertiary organic base such as triethylamine or l,8-diazabicyclo-[5.4.0]-undec-7-ene (DBU), conveniently in an inert organic solvent, for example a polar solvent such as dimethylformamide, the reaction temperature suitably being from 0 to 40°C, preferably ambient temperature. Replacement of a protective group R9 by hydrogen may be effected using known procedures; for example, where R9 is tert-butoxy-carbonyl, by treatment with a carboxylic acid such as trifluoroacetic acid. Replacement of a protecting group in R1 may be affected using known procedures, for example, when R1 contains a hydroxy group protected as an ether group, such as tert-butoxy, by treatment with HBr in a carboxylic acid such as acetic acid; when R9 is a protective group, this treatment also replaces R9 by hydrogen.
Compounds of formula III are commercially available or may be prepared by known methods.
Compounds of formula IV or V are known or may be prepared by known procedures or analogously e.g. as hereinafter described in the Examples.
Compounds of formula VI where X1 is -S- may be prepared by reacting a compound of formula XI Ar— SH XI where Ar is as hereinbefore defined, with a compound of formula XLT
in the presence of sodium hydride where R10 is a protecting group, and replacing R10 in the product by hydrogen, or analogously e.g. as hereinafter described in the Examples. The reaction may be carried out in an inert organic solvent such as dimethylformamide (DMF). Suitable reaction temperatures may be from 20°C to 150°C, conveniently from 50 to 70°C. The replacement of R10 by hydrogen may be effected using known procedures or analogously e.g. as hereinafter described in the Examples.
Compounds of formula VI where X1 is -S(=O)- may be prepared by reacting the corresponding aryl-sulfanyl-azetidine, preferably a protected form thereof, with an oxidising agent such as a per-benzoic acid, or analogously e.g. as hereinafter described in the Examples. The reaction is conveniently carried out in an organic solvent such as dichloromethane (DCM). The reaction temperature may be e.g. from 5 to 25 °C, preferably about 15 °C. Compounds of formula VI where X1 is -S(=O)2- may be prepared by reacting the corresponding aryl-sulfanyl-azetidine, preferably a protected form thereof, with an oxidising agent such as a per-benzoic acid, or analogously e.g. as hereinafter described in the Examples. The reaction is conveniently carried out in an organic solvent such as dichloromethane (DCM). The reaction temperature may be e.g. from 5 to 25 °C, preferably about 15 °C.
Compounds of formula VII are known or may be prepared by known procedures or analogously e.g. as hereinafter described in the Examples.
Compounds of formula VIII where X2 is -C(=O)- may be prepared by reacting a compound of formula XIII or XIV
with a compound of formula XV Ar=MgBr XV where Ar and R11 are as hereinbefore defined, and replacing R11 in the product by hydrogen, or analogously e.g. as hereinafter described in the Examples. Reaction of compounds of formulae Xπi/XIV and XV may be effected in an inert organic solvent, e.g. an ether such as THF and/or diethyl ether; suitable reaction temperatures may be from -10°C to 10°C, conveniently from -5 to 5°C. Replacement of R11 in the product by hydrogen may be effected using known procedures or analogously e.g. as hereinafter described in the Examples.
Compounds of formula VIII where X2 is -O- may be prepared by reacting a compound of formula XVI
with a compound of formula Ar-OH in the presence of sodium hydride, where Ar is as hereinbefore defined and R12 is a protecting group, and replacing R12 in the product by hydrogen, or analogously e.g. as hereinafter described in the Examples. The reaction may be carried out in an inert organic solvent such as DMF. Suitable reaction temperatures may be from 20°C to 150°C, conveniently from 50 to 70°C. The replacement of R12 by hydrogen may be effected using known procedures or analogously e.g. as hereinafter described in the Examples.
Compounds of formula VIII where X2 is -CH2- are novel and may be prepared by reduction of compounds of formula VHI where X2 is -C(=O) -, for example using known reduction procedures or analogously e.g. as hereinafter described in the Examples. This preferably involves of reduction to the corresponding alcohol, conversion to the iodine and then reduction.
Compounds of formula Vϋl where X2 is -S- may be prepared by reacting a compound of formula XVII Ar— SH XVII where Ar is as hereinbefore defined, with a compound of formula XVHI XVIII in the presence of sodium hydride where R13 is a protecting group, and replacing R13 in the product by hydrogen, or analogously e.g. as hereinafter described in the Examples. The reaction may be carried out in an inert organic solvent such as dimethylformamide (DMF). Suitable reaction temperatures may be from 20°C to 150°C, conveniently from 50 to 70°C. The replacement of R13 by hydrogen may be effected using known procedures or analogously e.g. as hereinafter described in the Examples.
Compounds of formula VIII where X2 is -S(=O)- may be prepared by reacting the corresponding aryl-sulfanyl-azetidine, preferably a protected form thereof, with an oxidising agent such as a per-benzoic acid, or analogously e.g. as hereinafter described in the Examples. The reaction is conveniently carried out in an organic solvent such as dichloromethane (DCM). The reaction temperature may be e.g. from 5 to 25 °C, preferably about 15 °C.
Compounds of formula VIII where X2 is -S(=O)2- may be prepared by reacting the corresponding aryl-sulfanyl-azetidine, preferably a protected form thereof, with an oxidising agent such as a per-benzoic acid, or analogously e.g. as hereinafter described in the Examples. The reaction is conveniently carried out in an organic solvent such as dichloromethane (DCM). The reaction temperature may be e.g. from 5 to 25 °C, preferably about 15 °C.
Compounds of formulae IX , X, XI or XII are known or may be prepared by known procedures or analogously e.g. as hereinafter described in the Examples.
Compounds of formula XIII may be prepared by reacting a compound of formula XIX
where R11 is as hereinbefore defined, with O,N-dimethylhydroxylamine hydrochloride in the presence of a peptide coupling agent such as di-imidazol-1-yl-methanone, conveniently in an inert organic solvent such as THF, suitably at reflux temperature, or analogously e.g. as hereinafter described in the Examples.
Compounds of formula XIV, XV, XVI, XVH, XVIII or XLX are known or may be prepared by known procedures or analogously e.g. as hereinafter described in the Examples.
Where reference is made herein to protected functional groups or to protecting groups, the protecting groups may be chosen in accordance with the nature of the functional group, for example as described in Protective Groups in Organic Synthesis, T. W. Greene, P.G.M. Wuts, John Wiley &c Sons Inc, Third Edition, 1999, which reference also describes procedures suitable for replacement of the protecting groups by hydrogen.
Compounds of formula la or lb in free form may be converted into salt form, and vice versa, in a conventional manner. The compounds in free or salt form can be obtained in the form of hydrates or solvates containing a solvent used for crystallization. Compounds of formula la or lb can be recovered from reaction mixtures and purified in a conventional manner. Isomers, such as enantiomers, may be obtained in a conventional manner, e.g. by fractional crystallization or asymmetric synthesis from correspondingly asymmetrically substituted, e.g. optically active, starting materials.
Compounds of formula la or lb in free or pharmaceutically acceptable salt form, hereinafter referred to alternatively as agents of the invention, are useful as pharmaceuticals. Accordingly the invention also provides a compound of formula la or lb in free or pharmaceutically acceptable salt form for use as a pharmaceutical. The agents of the invention act as CCR-3 receptor antagonists, thereby inhibiting the infiltration and activation of inflammatory cells, particularly eosinophils, and inhibiting allergic response. The inhibitory properties of agents of the invention can be demonstrated in the following assay:
In this assay the effect of agents of the invention on the binding of human eotaxin to human CCR-3 is determined. Recombinant cells expressing human CCR-3 are captured by wheatgerm agglutinin (WGA) polyvinyltoluidene (PVT) SPA beads (available from Amersham), through a specific interaction between the WGA and carbohydrate residues of glycoproteins on the surface of the cells. [125I]-human eotaxin (available from Amersham) binds specifically to CCR- 3 receptors bringing the [125I]-human eotaxin in close proximity to the SPA beads. Emitted a- particles from the [125I]-human eotaxin excite, by its proximity, the fluorophore in the beads and produce light. Free [125I]-human eotaxin in solution is not in close proximity to the scintillant and hence does not produce light. The scintillation count is therefore a measure of the extent to which the test compound inhibits binding of the eotaxin to the CCR-3.
Preparation of Assay Buffer: 5.96 g HEPES and 7.0 g sodium chloride are dissolved in distilled water and 1M aqueous CaCl2 (1 ml) and 1M aqueous MgCl2 (5 ml) are added. The pH is adjusted to 7.6 with NaOH and the solution made to a final volume of 1 L using distilled water. 5 g bovine serum albumin and 0.1 g sodium azide are then dissolved in the solution and the resulting buffer stored at 4°C. A Complete™ protease inhibitor cocktail tablet (available from Boehringer) is added per 50 ml of the buffer on the day of use.
Preparation of Homogenisation Buffer: Tris-base (2.42 g) is dissolved in distilled water, the pH of the solution is adjusted to 7.6 with hydrochloric acid and the solution is diluted with distilled water to a final volume of 1 1. The resulting buffer is stored at 4°C. A Complete™ protease inhibitor cocktail tablet is added per 50 ml of the buffer on the day of use.
Preparation of membranes: Confluent rat basophil leukaemia (RBL-2H3) cells stably expressing CCR3 are removed from tissue culture flasks using enzyme-free cell dissociation buffer and resuspended in phosphate-buffered saline. The cells are centrifuged (800 g, 5 minutes), the pellet resuspended in ice-cold homogenisation buffer using 1 ml homogenisation buffer per gram of cells and incubated on ice for 30 minutes. The cells are homogenised on ice with 10 strokes in a glass mortar and pestle. The homogenate is centrifuged (800 g, 5 minutes, 4°C), the supernatant further centrifuged (48,000 g, 30 minutes, 4°C) and the pellet redissolved in Homogenisation Buffer containing 10% (v/v) glycerol. The protein content of the membrane preparation is estimated by the method of Bradford (Anal. Biochem. (1976) 72:248) and aliquots are snap frozen and stored at -80°C.
The assay is performed in a final volume of 250 ul per well of an Optiplate™ microplate (ex Canberra Packard). To selected wells of the microplate are added 50 μl of solutions of a test compound in Assay Buffer containing 5 % DMSO (concentrations from 0.01 nM to 10 μM). To determine total binding, 50 μl of the Assay Buffer containing 5 % DMSO is added to other selected wells. To determine non-specific binding, 50 μl of 100 nM human eotaxin (ex R&D Systems) in Assay Buffer containing 5 % DMSO is added to further selected wells. To all wells are added 50 μl [125I]-Human eotaxin (ex Amersham) in Assay Buffer containing 5 % DMSO at a concentration of 250 pM (to give a final concentration of 50 pM per well), 50 μl of WGA- PVT SPA beads in Assay Buffer (to give a final concentration of 1.0 mg beads per well) and 100 μl of the membrane preparation at a concentration of 100 μg protein in Assay Buffer (to give a final concentration of 10 μg protein per well). The plate is then incubated for 4 hours at room temperature. The plate is sealed using TopSeal-S™ sealing tape (ex Canberra Packard) according to the manufacturer's instructions. The resulting scintillations are counted using a Canberra Packard TopCount™ scintillation counter, each well being counted for 1 minute. The concentration of test compound at which 50% inhibition occurs (IGo) is determined from concentration-inhibition curves in a conventional manner.
The compounds of the Examples hereinbelow generally have IGo values below 1 μM in the above assay. For instance, the compounds of Examples 1, 19, 25, 31, 73, 94 and 131 have IGo values of 0.278, 0.002, 0.820, 0.117, 0.136, 0.124 and 0.096 μM respectively.
Most of the compounds of the Examples exhibit selectivity for inhibition of CCR-3 binding relative to inhibition of binding of the alpha-1 adrenergic receptor. Some of the compounds e.g. those of Example 19 and 31, are also histamine HI antagonists.
The inhibitory properties of agents of the invention on binding of the alpha-1 adrenergic receptor can be determined in the following assay:
Cerebral cortices from male Sprague-Dawley rats (175-200 g) are dissected and homogenised in 10 volumes of ice cold 0.32 M sucrose (containing 1 mM MgCl2 dihydrate and ImM K2HPO ) with a glass/Teflon homogeniser. The membranes are centrifuged at 1000 x g for 15 miN, the pellet discarded and the centrifugation repeated. The supernatants are pooled and centrifuged at 18,000 x g for 15 minutes. The pellet is osmotically shocked in 10 volumes of water and kept on ice for 30 minutes. The suspension is centrifuged at 39,000 x g for 20 minutes, resuspended in Krebs-Henseleit buffer pH 7.4 (1.17 mM MgS0 anhydrous, 4.69 mM KG, 0.7 mM K2HPO4 anhydrous, 0.11 M NaCl, 11 mM D-glucose and 25 mM NaHCO3) containing 20 mM Tris, and kept for 2 days at -20°C. The membranes are then thawed at 20- 23°C, washed three times with Krebs-Henseleit buffer by centrifugation at 18,000 x g for 15 minutes, left overnight at 4°C and washed again three times. The final pellet is resuspended with a glass/Teflon homogeniser in 125 ml/100 membranes in the same buffer. A sample is taken to determine the protein concentration (using the Bradford Assay with gamma globulin as the standard) and the remainder aliquoted and stored at -80°C.
The resulting membranes are subjected to a radioligand binding assay. The assay is conducted in triplicate using 96 well plates containing [125I]-HEAT (Amersham) (40 pM, ICj: 58.9 ± 18.7 pM), unlabelled test compound and membrane (57.1 μg/ml) to yield a final volume of 250 μl (assay buffer containing 50 mM Tris-base and 0.9% (w/v) NaCl, pH 7.4). The plates are incubated at 37°C for 60 minutes, after which rapid vacuum filtration over Whatman™ GF/C 96 well filter plates is carried out. Each plate is then washed three times with 10ml of ice cold assay buffer using a Brandel Cell harvester (Gaithersburg, MD). Following drying of the plates for 3 h. at 50°C, 40 μl of Microscint 20 is added to each well, the plates incubated at room temperature for a further 20 minutes and the retained radioactivity quantified in a Packard TopCount NXT™ scintillation counter.
Stock solutions of test compounds are dissolved initially in 100 % DMSO and diluted with assay buffer to the required concentrations to yield 1 % (v/v) DMSO. The concentration of test compound at which 50% inhibition occurs (IGo) is determined from concentration- inhibition curves in a conventional manner.
Having regard to their inhibition of binding of CCR-3, agents of the invention are useful in the treatment of conditions mediated by CCR-3, particularly inflammatory or allergic conditions. Treatment in accordance with the invention may be symptomatic or prophylactic.
Accordingly, agents of the invention are useful in the treatment of inflammatory or obstructive airways diseases, resulting, for example, in reduction of tissue damage, bronchial hyper- reactivity, remodelling or disease progression. Inflammatory or obstructive airways diseases to which the present invention is applicable include asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise-induced asthma, occupational asthma and asthma induced following bacterial or viral infection. Treatment of asthma is also to be understood as embracing treatment of subjects, e.g. of less than 4 or 5 years of age, exhibiting wheezing symptoms and diagnosed or diagnosable as "wheezy infants", an established patient category of major medical concern and now often identified as incipient or early-phase asthmatics. (For convenience this particular asthmatic condition is referred to as "wheezy- infant syndrome".)
Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g. of acute asthmatic or bronchoconstrictor attack, improvement in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, i.e. therapy for or intended to restrict or abort symptomatic attack when it occurs, for example anti-inflammatory (e.g. cortico- steroid) or bronchodilatory. Prophylactic benefit in asthma may in particular be apparent in subjects prone to "morning dipping". "Morning dipping" is a recognised asthmatic syndrome, common to a substantial percentage of asthmatics and characterised by asthma attack, e.g. between the hours of about 4 to 6 am, i.e. at a time normally substantially distant form any previously administered symptomatic asthma therapy.
Other inflammatory or obstructive airways diseases and conditions to which the present invention is applicable include acute lung injury (ALI), acute/adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD, CO AD or COLD), including chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular other inhaled drug therapy. The invention is also applicable to the treatment of bronchitis of whatever type or genesis including, e.g., acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis. Further inflammatory or obstructive airways diseases to which the present invention is applicable include pneumoconiosis (an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts) of whatever type or genesis, including, for example, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis. Having regard to their anti-inflammatory activity, in particular in relation to inhibition of eosinophil activation, agents of the invention are also useful in the treatment of eosinophil related disorders, e.g. eosinophilia, in particular eosinophil related disorders of the airways (e.g. involving morbid eosinophilic infiltration of pulmonary tissues) including hyper- eosinophilia as it effects the airways and/or lungs as well as, for example, eosinophil-related disorders of the airways consequential or concomitant to Loffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma and eosinophil-related disorders affecting the airways occasioned by drug-reaction.
Agents of the invention are also useful in the treatment of inflammatory or allergic conditions of the skin, for example psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis bullosa acquisita, and other inflammatory or allergic conditions of the skin.
Agents of the invention may also be used for the treatment of other diseases or conditions, in particular diseases or conditions having an inflammatory component, for example, treatment of diseases and conditions of the eye such as conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, diseases affecting the nose including allergic rhinitis, e.g. atrophic, chronic, or seasonal rhinitis, inflammatory conditions of the gastrointestinal tract, for example inflammatory bowel disease such as ulcerative colitis and Crohn's disease, diseases of the boneand joints including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and systemic sclerosis, and other diseases such as cyctic fibrosis, pulmonary hypertension, atherosclerosis, multiple sclerosis, diabetes (type I), myasthenia gravis, hyper IgE syndrome and acute and chronic allograft rejection, e.g. following transplantation of heart, kidney, liver, lung or bone marrow.
The effectiveness of an agent of the invention in inhibiting inflammatory conditions, for example in inflammatory airways diseases, may be demonstrated in an animal model, e.g. a mouse or rat model, of airways inflammation or other inflammatory conditions, for example as described by Szarka et al,/. Immunol. Methods (1997) 202:49-57; Renzi et al, Am. Rev. Respir. Dis. (1993) 148:932-939; Tsuyuki et al. . Clin. Invest. (1995) 96:2924-2931; and Cernadas et al (1999) Am. J. Respir. Cell Mol. Biol. 20:1-8. The agents of the invention are also useful as co-therapeutic agents for use in combination with other drug substances such as anti-inflammatory, bronchodilatory, antihistamine or anti- tussive drug substances, particularly in the treatment of obstructive or inflammatory airways diseases such as those mentioned hereinbefore, for example as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs. An agent of the invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance.
Such anti-inflammatory drugs include steroids, in particular gluco-corticosteroids such as budesonide, beclamethasone, fluticasone, ciclesonide or mometasone, or steroids described in WO 02/88167, WO 02/12266, WO 02/100879, WO 04/039827 or WO 02/00679, especially those of Examples 3, 11, 14, 17, 19, 26, 34, 37, 39, 51, 60, 67, 72, 73, 90, 99 and 101; LTB4 antagonists such as those described in US 5451700, also LY293111, CGS025019C, CP- 195543, SC-53228, BILL 284, ONO 4057 and SB 209247; LTD4 antagonists such as montelukast and zafirlukast; Dopamine receptor agonists such as cabergoline, bromocriptine, ropinirole and 4-hydroxy-7- [2- [ [2- [ [3 - (2-phenylethoxy)propyl] sulfonyl] ethyl] -amino] ethyl] - 2(3H)-benzothiazolone and pharmaceutically acceptable salts thereof (the hydrochloride being Viozan® - AstraZeneca); PDE4 inhibitors such as cilomilast (Ariflo® GSK), Roflumilast (Byk Gulden), V-11294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering-Plough), Arofylline (Almirall Prodesfarma), PD189659 / PD168787 (Parke-Davis), AWD-12-281 (Asta Medica), CDC-801 (Celgene), SelCID(TM) CC-10004 (Celgene), VM554/UM565 (Vernalis), T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo), WO 92/19594, WO 93/19749, WO 93/19750, WO 93/19751, WO 99/16766, WO 01/13953, WO 03/104204, WO 03/104205, WO 04/000814, WO 04/000839 and WO 04/005258, WO 04018450, WO 04/018451, WO 04/018457, WO 04/018465, WO 04/018431, WO 04/018449, WO 04/018450, WO 04/018451, WO 04/018457, WO 04/018465, WO 04/019944, WO 04/019945 and WO 04/045607, WO 04/037805 as well as those described in WO 98/18796 and WO 03/39544; A2a agonists such as those described in EP 409595A2, EP 1052264, EP 1241176, WO 94/17090, WO 96/02543, WO 96/02553, WO 98/28319, WO 99/24449, WO 99/24450, WO 99/24451, WO 99/38877, WO 99/41267, WO 99/67263, WO 99/67264, WO 99/67265, WO 99/67266, WO 00/23457, WO 00/77018, WO 00/78774, WO 01/23399, WO 01/27130, WO 01/27131, WO 01/60835, WO 01/94368, WO 02/00676, WO 02/22630, WO 02/96462, WO 03/086408, WO 04/039762, WO 04/039766, WO 04/045618, WO 04/046083; and A2b antagonists such as those described in WO 02/42298. Such bronchodilatory drugs include anticholinergic or antimuscarinic agents, in particular ipratropium bromide, oxitropium bromide, tiotropium bromide, CHF 4226 (Chiesi) and glycopyrrolate, but also those described in WO 01/04118, WO 02/51841, WO 02/53564, WO 03/00840, WO 03/87094, WO 04/05285, WO 02/00652, WO 03/53966, EP 424021, US 5171744, US 3714357, US 5171744, WO 03/33495 and WO 04/018422; and beta (β)-2- adrenoceptor agonists such as albuterol (salbutamol), metaproterenol, terbutaline, salmeterol, fenoterol, procaterol, and especially, formoterol and pharmaceutically acceptable salts thereof, and compounds (in free or salt or solvate form) of formula (I) of WO 00/75114, which document is incorporated herein by reference, preferably compounds of the Examples thereof, especially a compound of formula
OH and pharmaceutically acceptable salts thereof, as well as compounds (in free or salt or solvate form) of formula (I) of WO 04/16601. Further suitable β -2-adrenoreceptor agonists include compounds such as those described in JP 05025045, US 2002/0055651, WO 93/18007, WO 99/64035, WO 01/42193, WO 01/83462, WO 02/066422, WO 02/070490, WO 02/076933, WO 03/24439, WO 03/72539, WO 03/42160, WO 03/91204, WO 03/42164, WO 03/99764, WO 04/11416, WO 04/16578, WO 04/22547, WO 04/32921, WO 04/33412, WO 04/37773, WO 04/37807, WO 04/39762, WO 04/39766, WO 04/45618 and WO 04/46083.
Such co-therapeutic antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine as well as those disclosed in JP 2004107299, WO 03/99807 and WO 04/26841.
Combinations of agents of the invention and one or more steroids, beta-2 agonists, PDE4 inhibitors or LTD4 antagonists may be used, for example, in the treatment of COPD or, particularly, asthma. Combinations of agents of the invention and anticholinergic or antimuscarinic agents, PDE4 inhibitors, dopamine receptor agonists or LTB4 antagonists may be used, for example, in the treatment of asthma or, particularly, COPD. Other useful combinations of agents of the invention with anti-inflammatory drugs are those with other antagonists of chemokine receptors, e.g. CCR-1, CCR-2, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, particularly CCR-5 antagonists such as Schering-Plough antagonists SC-351125, SCH-55700 and SCH-D, Takeda antagonists such as N-[[4-[[[6,7-dihydro-2-(4-methylρhenyl)-5H-benzo- cyclohepten- 8 -yl] carbonyl] amino] phenyl] -methyl] tetrahydro-N,N-dimethyl-2H-pyran-4- aminium chloride (TAK-770), CCR-5 antagonists described in US 6166037 (particularly claims 18 and 19), WO 00/66558 (particularly claim 8), and WO 00/66559 (particularly claim 9), WO 04/018425 and WO 04/026873.
In accordance with the foregoing, the invention also provides a method for the treatment of a condition mediated by CCR-3, for example an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease, which comprises administering to a subject, particularly a human subject, in need thereof an effective amount of a compound of formula la or lb in a free or pharmaceutically acceptable salt form as hereinbefore described. In another aspect the invention provides the use of a compound of formula la or lb, in free or pharmaceutically acceptable salt form, as hereinbefore described for the manufacture of a medicament for the treatment of a condition mediated by CCR-3, e.g. an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease.
The agents of the invention may be administered by any appropriate route, e.g. orally, for example in the form of a tablet or capsule; parenterally, for example intravenously; by inhalation, for example in the treatment of inflammatory or obstructive airways disease; intranasally, for example in the treatment of allergic rhinitis; topically to the skin, e.g. in the treatment of atopic dermatitis; or rectally, e.g. in the treatment of inflammatory bowel disease.
In a further aspect, the invention also provides a pharmaceutical composition comprising as active ingredient a compound of formula la or lb in free or pharmaceutically acceptable salt form, optionally together with a pharmaceutically acceptable diluent or carrier therefor. The composition may contain a co-therapeutic agent such as an anti-inflammatory bronchodilatory or antihistamine drug as hereinbefore described. Such compositions may be prepared using conventional diluents or excipients and techniques known in the galenic art. Thus oral dosage forms may include tablets and capsules. Formulations for topical administration may take the form of creams, ointments, gels or transdermal delivery systems, e.g. patches. Compositions for inhalation may comprise aerosol or other atomizable formulations or dry powder formulations.
When the composition comprises an aerosol formulation, it preferably contains, for example, a hydro-fluoro-alkane (HFA) propellant such as HFA134a or HFA227 or a mixture of these, and may contain one or more co-solvents known in the art such as ethanol (up to 20% by weight), and/or one or more surfactants such as oleic acid or sorbitan trioleate, and/or one or more bulking agents such as lactose. When the composition comprises a dry powder formulation, it preferably contains, for example, the compound of formula la or lb having a particle diameter up to 10 microns, optionally together with a diluent or carrier, such as lactose, of the desired particle size distribution and a compound that helps to protect against product performance deterioration due to moisture e.g. magnesium stearate. When the composition comprises a nebulised formulation, it preferably contains, for example, the compound of formula la or lb either dissolved, or suspended, in a vehicle containing water, a co-solvent such as ethanol or propylene glycol and a stabiliser, which may be a surfactant.
The invention includes (A) an agent of the invention in inhalable form, e.g. in an aerosol or other atomisable composition or in inhalable particulate, e.g. micronised form, (B) an inhalable medicament comprising an agent of the invention in inhalable form; (C) a pharmaceutical product comprising such an agent of the invention in inhalable form in association with an inhalation device; and (D) an inhalation device containing an agent of the invention in inhalable form.
Dosages of agents of the invention employed in practising the present invention will of course vary depending, for example, on the particular condition to be treated, the effect desired and the mode of administration. In general, suitable daily dosages for administration by inhalation are of the order of 0.01 to 30 mg/kg while for oral administration suitable daily doses are of the order of 0.01 to 100 mg/kg.
The invention is illustrated by the following Examples. EXAMPLES
Compounds of formula la that are also formula XX
where Ar, X1 and R3 are as shown in Table 1 below, the methods of preparation being described hereinafter. The table also shows characterising mass spectrometry data. The compounds are all in free form.
TABLE 1
Preparation of Intermediates
f(S)-l-(tert-butyl-diphenyl-silanyloxymethyl)-3-iodo-propyl]-carbamic acid tert-butyl ester:
(a) (S)-3-tert-Butoxycarbonylamino-4-(tert-butyl-diphenyl-silanyloxy)-butyric acid benzyl ester A solution of (S)-3-tert-butoxycarbonylamino-4-hydroxy-butyric acid benzyl ester (1.34 g, 4.37 mmol) (prepared using the method of Rodriguez, Marc; Linares, Muriel; Doulut, Sylvie; Heitz, Annie; Martinez, Jean; Tetrahedron Lett. (1991), 32(7), 923-6. ) and imidazole (0.88 g, 13.01 mmol in dimethylformamide (7 ml) is treated with tertbutyldiphenylsilyl chloride (1.69 ml, 6.5 mmol). The reaction mixture is stirred together at room temperature for 1 hour, then diluted with water and extracted into ethyl acetate. The ethyl acetate phase is dried over MgSO4 and evaporated. The crude product is purified by flash silica chromatography (elution with 1:1 ethyl acetate/hexane) to afford (S)-3-tert-butoxycarbonylamino-4-(tert-butyl-diphenyl- silanyloxy)-butyric acid benzyl ester. [M-BOC] 448.0.
(b) [(S)-l-(tert-Butyl-diphenyl-silanyloxymethyl)-3-hydroxy-propyl]-carbamic acid tert-butyl ester
A solution of (S)-3-tert-butoxycarbonylamino-4-(tert-butyl-diphenyl-silanyloxy)-butyric acid benzyl ester in (2.37 g, 4.33 mmol) in dry diethylether (25 ml) at 0°C is treated with a 2 M solution of lithium borohydride in THF (4.33 ml). The reaction mixture is allowed to warm to ambient temperature and stirred for 3 hours under argon, then quenched by addition of water (10 ml) and 0.5 M aqueous citric acid solution (20 ml). The ether is separated, and the aqueous phase extracted with more ether. The combined ether phases are dried over MgSO4 and evaporated. The crude product is purified by flash silica chromatography on a biotage column (90 g) (elution with a 1:3 ethyl acetate/hexane then methanol ) to afford [(S)-l-(tert-butyl- diphenyl-silanyloxymethyl)-3-hydroxy-propyl]-carbamic acid tert-butyl ester [M-BOC] 344.1. (c) [(S)-l-(tert-Butyl-diphenyl-silanyloxymethyl)-3-iodo-propyl]-carbamic acid tert-butyl ester A suspension of polystyrene resin-bound triphenylphosphine (2.33 g, 3 mmol/g) in dry dichloromethane (25 ml) is treated with iodine (1.56 g, 6.16 mmol) and stirred for 15 minutes under argon . Imidazole (0.477 g, 7.0 mmol) is added and the reaction mixture stirred at room temperature for a further 15 minutes. The reaction mixture is then treated with a solution of [(S)-l-(tert-butyl-diphenyl-silanyloxymethyl)-3-hydroxy-propyl]-carbamic acid tert-butyl ester (1.24 g, 2.8 mmol) in dichloromethane (5 ml). The reaction mixture is refluxed for 2 hours under argon, then filtered through a Celite™ filter pad, washing with dichloromethane. The filtrate is washed with 5% aqueous sodium thiosulphate solution and water, dried over MgSO4 and evaporated. The crude product is purified by flash silica chromatography (elution with 1:99 methanol/dichloromethane) to afford [(S)-l-(tert-butyl-diphenyl-silanyloxymethyl)-3-iodo- propyl] -carbamic acid tert-butyl ester. [M-BOC] 453.9.
((S)-3-Iodo-l-methoxymethyl-propyl)-carbamic acid tert-butyl ester:
(a) (S)-3-tert-Butoxycarbonylamino-4-methoxy-butyric acid benzyl ester A solution of (S)-3-tert-butoxycarbonylamino-4-hydroxy-butyric acid benzyl ester (31.4 g, 101 mmol) (prepared using the method of Rodriguez, Marc; Linares, Muriel; Doulut, Sylvie; Heitz, Annie; Martinez, Jean ^Tetrahedron Lett. (1991), 32(7), 923-6. ) in dichloromethane (280 ml) is cooled to -20°C and a 48% aqueous solution of tetrafluoroboric acid ( 13.3 ml, 101 mmol) added. With vigorous stirring is added dropwise a 2.0 M solution of trimethylsilyl- diazomethane (50.8 ml, 101 mmol) ) in hexane over 35 minutes. After stirring for a further 30 minutes, a second aliquot of trimethylsilyldiazomethane is added (12.7 ml, 25 mmol) slowly over 10 minutes. After stirring for a further 30 minutes at -20°C a further aliquot of trimethylsilyl-diazomethane (12.7 ml, 25 mmol) is added over 10 minutes. This pattern is continued until a total of 127 ml of trimethylsilyldiazomethane solution (254 mmol) is added. After the last addition the reaction mixture is left to stir for 1.5 hours at -20°C. The reaction mixture is then quenched with water and extracted into dichloromethane. The organic phase is dried over magnesium sulphate and evaporated. The crude product is purified by flash silica chromatography (elution with 2:8 ethylacetate / hexane) to afford (S)-3-tert-Butoxycarbonyl- amino-4-methoxy-butyric acid benzyl ester as a clear oil . [M-BOC] 224.19. (b) f(S)-3-Hydroxy-l-methoxymethy1-propyl)-carbamic acid tert-butyl ester
A solution of (S)-3-tert-Butoxycarbonylamino-4-methoxy-butyric acid benzyl ester (10.4 g, 32.3 mmol) in dry diethylether (70 ml) cooled to 0°C is treated slowly with a 2.0 M solution of LiBH in THF (32.2 ml, 64.4 mmol). The reaction mixture is allowed to warm to ambient temperature and then left to stir. After 6 hours the reaction mixture is quenched slowly with 0.5 M aqueous solution of citric acid and extracted with ether. The ether phase is dried over magnesium sulphate and evaporated. The crude product is purified by flash silica chromatography (elution with a gradient 3:7 to 6:4 ethylacetate/hexane) to afford ((S)-3-Hydroxy-l- methoxymethyl-propyl)-carbamic acid tert-butyl ester as a clear oil. [M-BOC] 120.13
(c) ((S)-3-Iodo-l-methoxymethyl-propyl)-carbamic acid tert-butyl ester
A suspension of polystyrene resin-bound triphenylphosphine (18.645 g, 3 mmol/g) in dry dichloromethane (250 ml) is treated with iodine (12.5 g, 49.22 mmol) and stirred for 15 minutes under argon . Imidazole (3.87 g, 55.94 mmol) is added and the reaction mixture stirred at room temperature for a further 15 minutes. The reaction mixture is then treated with a solution of ((S)-3-Hydroxy-l-methoxymethyl-propyl)-carbamic acid tert-butyl ester ( 4.9 g, 22.37 mmol) in dichloromethane (30 ml), and refluxed for 1.5 hours under argon. The resin is removed by filtration through a Celite™ filter material pad, washing with dichloromethane. The filtrate is washed with 5% aqueous sodium thiosulphate solution and water, dried over MgSO and evaporated to afford ((S)-3-Iodo-l-methoxymethyl-propyl)-carbamic acid tert- butyl ester as a crude oil. [M-BOC] 230.06.
((R)-3-iodo-l-methyl-propyl)-carbamic acid tert-butyl ester:
(a) (S)-3-tert-Butoxycarbonylamino-4-iodo-butyric acid benzyl ester
A suspension of polymer bound triphenyl phosphine (18.25 g, 54.76 mmol) in DCM (100 ml) is treated with iodine (12.2 g, 48.1 mmol) and the reaction mixture stirred at ambient temperature for 15 minutes. Imidazole (3.72 g, 54.7 mmol) is added and the reaction mixture stirred for a further 15 minutes. A solution of (S)-3-tert-butoxycarbonylamino-4-hydroxy- butyric acid benzyl ester (6.76 g, 21.9 mmol) in DCM (100 ml) is added. The suspension is stirred at reflux for 1.5 hours, then filtered through Celite™ filter material, washing through with DCM. The combined organic phase is washed with an aqueous solution of 10% sodium thiosulphate, water and brine, then dried over magnesium sulphate and evaporated. The crude product is chromatographed over flash silica using 8% ethylacetate in iso-hexane as eluent to afford (S)-3-tert-butoxycarbonylamino-4-iodo-butyric acid benzyl ester. [ M-BOC] 320.12
(b) ((R)-3-Hydroxy-l-methyl-propyl)-carbamic acid tert-butyl ester
A solution of (S)-3-tert-butoxycarbonylamino-4-iodo-butyric acid benzyl ester (0.2 g, 0.477 mmol) in dry diethylether (3 ml) cooled to 0°C under argon, is treated with a 2.0 M solution of lithium borohydride in THF (0.95 ml, 1.9 mmol). The reaction mixture is allowed to warm to ambient temperature with stirring for 18 hours. The reaction is quenched by addition of water and partitioned between ethylacetate and 10% citric acid solution. The organic phase is washed with brine, dried over magnesium sulphate and evaporated. The crude product is purified by flash silica chromatography using 1% methanol in DCM as eluent to afford ((R)-3- hydroxy-l-methyl-propyl)-carbamic acid tert-butyl ester, (c) ((R)-3-Iodo-l-methyl-propyl)-carbamic acid tert-butyl ester A suspension of polymer bound triphenyl phosphine (0.200 g, 0.595 mmol) in DCM (2 ml) is treated with iodine (0.133 g, 0.523 mmol) and the reaction mixture stirred at ambient temperature for 15 minutes. Imidazole (39 mg, 0.57 mmol) is added and the reaction mixture stirred for a further 15 minutes. A solution of ((R)-3-Hydroxy-l-methyl-propyl)-carbamic acid tert-butyl ester (0.045 g, 0.238 mmol) in DCM (2 ml) is added. The suspension is stirred at reflux for 2.5 hours, then filtered through Celite™ filter material, washing through with DCM. The combined organic phase is washed with an aqueous solution of 10% sodium thiosulphate, water and brine, then dried over magnesium sulphate and evaporated to afford ((R)-3-iodo-l- methyl-propyl)-carbamic acid tert-butyl ester. [ M+H] 285.05
5-Ethyl-isoxazol-3-ylamine:
(a) (2-Ethyl-[1.3]dioxolan-2-yl)-acetonitrile
A solution of 3-oxo-pentanenitrile (1.582 g, 16.49mmol), ethylene glycol (1.026 ml, 84.59 mmol) and a catalytic amount of p-Toluene sulphonic acid (8 mg) in Toluene (10 ml) is refluxed at 150°C for 2 days using Dean-Stark apparatus. The reaction mixture is diluted with ethyl acetate and washed with saturated sodium bicarbonate solution. The organic phase is dried over MgSO , filtered, and the solvent evaporated to yield (2-ethyl-[l,3]dioxolan-2-yl)- acetonitrile. IH NMR (400MHz, CDC13) d 4.15(2H,m), 4.05 (2H, m), 2.65 (2H, s), 1.80 (2H, q), 0.95 (3H, t)
(b) 2-(2-Ethyl [1.3]dioxolan-2-yl)-N-hydroxy-acetamidine.
A solution of NaOH (1.17 g, 29.3 mmol) in water/methanol (1:1) (1 8ml), cooled to 0°C in an ice bath, is treated with hydroxylamine hydrochloride (1.58 g, 22.78 mmol), with stirring for 5 minutes. (2-Ethyl-[l,3]dioxolan-2-yl)-acetonitrile (1.42 g, 10.125 mmol) is added and the reaction mixture stirred at room temperature for 18 hours, then refluxed for a further 2 hours. The reaction mixture is cooled and partitioned between ethyl acetate and water. The organic phase is dried over MgSO4, filtered, and the solvent evaporated to yield 2-(2-Ethyl [l,3]dioxolan-2-yl)-N-hydroxy-acetamidine. [M+H] 175.21 (c) 5-Ethyl-isoxazol-3-ylamine
A solution of 2-(2-ethyl [l,3]dioxolan-2-yl)-N-hydroxy-acetamidine (1.49 g 8.564 mmol) in ethanol (49 ml), acidified to pH 1 with concentrated hydrochloric acid solution, is refluxed at 50°C for 3 days. The solvent is evaporated and the crude product dissolved in water and extracted into ethyl acetate (x2). The organic phase is dried over MgSO and evaporated to afford 5-ethyl-isoxazol-3-ylamine. [M + H] 113.02
(5-Ethyl-[1.3.41thiadiazol-2-yl)-carbamic acid phenyl ester:
A solution of 5-Ethyl-[l,3,4]thiadiazol-2-ylamine (2.5g, 19.4mmol) and pyridine (1.72 ml, 21.3mmol) in dichloromethane (70 ml) is cooled to -70°C and treated with a solution of phenylchloroformate (2.45 ml, 19.6 mmol) in dichloromethane (10 ml) dropwise. The reaction mixture is allowed to warm to ambient temperature and stirred for 3 hours during which a precipitate forms. The precipitate is collected by filtration, and dried under vacuum to afford (5-Ethyl-[l,3,4]thiadiazol-2-yl)-carbamic acid phenyl ester as white solid. [M+H] 250.15
(5-Cyclopropyl-2-methyl-2H-pyrazol-3-yl)-carbamic acid phenyl ester: A solution of 5-Cyclopropyl-2-methyl-2H-pyrazol-3-ylamine (3.0 g, 22 mmol) (65 ml) and sodium bicarbonate (2 g, 24 mmol) in THF is cooled to 0°C. Phenylchloroformate (3.4 g, 22 mmol) is added dropwise over 15 minutes. The reaction mixture is allowed to warm to ambient temperature and stirred for 5 hours, then filtered and the filtrate partitioned between ethyl acetate and water. The organic phase is washed with water, 5% aqueous citric acid solution and brine, dried over MgSO4 and evaporated to afford (5-Cyclopropyl-2-methyl-2H- pyrazol-3-yl)-carbamic acid phenyl ester. [M+H] 258.17.
(5-Ethyl-2-methyl-2H-pyrazol-3-yl)-carbamic acid phenyl ester:
(a) 5-Ethyl-2-methyl-2H-pyrazol-3-ylamine
A solution of 3-Oxo-pentanenitrile (0.5 g, 5.15 mmol) and methylhydrazine (0.24 g, 5.15 mmol) in ethanol (5ml) is heated to reflux for 1.5 hours. The solvent is evaporated and the residue partitioned between ethyl acetate and brine. The organic phase is dried over MgSO4 and evaporated to afford 5-Ethyl-2-methyl-2H-pyrazol-3-ylamine. [M+H]
(b) (5-Ethyl-2-methyl-2H-pyrazol-3-yl)-carbamic acid phenyl ester
A solution of 5-Ethyl-2-methyl-2H-pyrazol-3-ylamine (10 g, 79.8 mmol) (500 ml) and potassium carbonate in THF (12.14 g, 87.8 mmol) is cooled to 0°C. Phenylchloroformate (10.15 ml, 80.6 mmol) is added dropwise over 20 minutes. The reaction mixture is stirred for 40 minutes at 0°C then allowed to warm to ambient temperature and stirred for a further 2.5 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic phase is washed with 5% aqueous citric acid solution and brine. The organic phase is treated with MgSO4 and charcoal then filtered and evaporated to afford (5-Cyclopropyl-2-methyl-2H- pyrazol-3-yl)-carbamic acid phenyl ester. [M+H] 246.21
5-Cyclobutyl-2-methyl-2H-pyrazol-3-yl)-carbamic acid phenyl ester:
(a) 5-Cyclobutyl-2-methyl-2H-pyrazol-3-ylamine
This is synthesized in an analogous manner to 5-ethyl-2-methyl-2H-pyrazol-3-ylamine except using 3-cyclobutyl-3-oxopropionitrile instead of 3-oxo-pentanenitrile.
(b) 5-Cyclobutyl-2-methyl-2H-pyrazol-3-yl)-carbamic acid phenyl ester
A solution of 5-Cyclobutyl-2-methyl-2H-pyrazol-3-ylamine (0.156 g, 1.03 mmol) in dimethylformamide (3 ml) cooled to 0°C, is treated with phenylchloroformate (0.13 ml, 1.03 mmol) dropwise and left to stir at 0°C for 1 hour. The reaction mixture is partitioned between ethyl acetate and 1.0 M hydrochloric acid solution, and the organic phase washed with water, dried over magnesium sulphate and evaporated to yield (5-Cyclobutyl-2-methyl-2H-pyrazol-3-yl)- carbamic acid phenyl ester. [M+H] 272.22
(2-Ethyl-2H-tetrazol-5-yl)-carbamic acid phenyl ester:
A solution of 2-ethyl-2H-tetrazol-5-ylamine (0.1 g, 0.88 mmol) in dry THF (2 ml) is treated with pyridine (0.09 ml, 1.10 mmol) followed by a solution of phenylchloroformate (0.11 ml, 0.911 mmol) in THF (1 ml). The reaction mixture is stirred at ambient temperature for 1.5 hours, then partitioned between ethyl acetate and water. The ethyl acetate phase is dried over magnesium sulphate and evaporated to afford (2-Ethyl-2H-tetrazol-5-yl)-carbamic acid phenyl ester as a white solid. IH NMR (CDC13, 400 MHz) δ, 7.90 (IH, brs), 7.30 (2H, ), 7.15, (3H, m), 4.60 (2H, q) 1.60 (3H, t).
(5-Ethyl-isoxazol-3-yl)-carbamic acid phenyl ester and (3-Ethyl-isoxazol-5yl)-carbamic acid phenyl ester are prepared analogously using 5-Ethyl-isoxazol-3-ylamine and 5-Ethyl-isoxazol- 5-ylamine respectively in place of 2-ethyl-2H-tetrazol-5-ylamine. Preparation of final compounds
Example 1 l-{(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-3-(3,5- dimethoxy-phenyl)-urea:
(a) l-Benzhydryl-3-(4-chloro-benzenesulfinyl -azetidine
A solution of l-Benzhydryl-3-(4-chloro-phenylsulfanyl)-azetidine (3.16 g, 8.6 mmol) in chloroform (30 ml) cooled to -15°C is treated slowly with a solution of meta chloro perbenzoic acid (2.17 g, 8.8 mmol) in chloroform over 2 hours. The reaction mixture is washed with water, aqueous saturated sodium bisulphate solution, sodium bicarbonate solution and brine. The organic phase is dries over magnesium sulphate and evaporated. The crude product is purified by flash silica chromatography (elution with iso-hexane : ether, 7:3 to 1:1) to afford l-Benzhydryl-3-(4-chlorobenzenesulfinyl)-azetidine, [MH]+ 384.12.
(b) 3-(4-Chloro-benzenesulfinyl)-azetidine
A solution of l-Benzhydryl-3-(4-chloro-phenylsulfinyl)-azetidine (2.6g, 6.8 mmol) in dichloromethane (35 ml) cooled to -4°C, is treated with 1-chloroethoxycarbonyl chloride (1.25 ml, 11.54 mmol) and the reaction mixture allowed to warm to room temperature with stirring for 18 hours. The solvent is evaporated and the residue taken up in methanol (15 ml) and stirred at room temperature for a further 18 hours. The solvent is evaporated and the residue crystallized from methanol/diethylether to afford 3-(4-Chloro-phenylsulfinyl)-azetidine. [MH]+ 218.06
(c) {(S)-l-(tert-Butyl-diphenyl-silanyloxymethyl -3-[3-(4-chloro-benzenesulfinyl)-azetidin-l-yl]- propyl}-carbamic acid tert-butyl ester
A solution of 3-(4-Chloro-phenylsulfinyl)-azetidine (1.17 g, 4.6 mmol), [(S)-l-(tert-Butyl- diphenyl-silanyloxymethyl)-3-iodo-propyl]-carbamic acid tert-butyl ester (2.8 g, 5.1 mmol) and triethylamine (2.6 ml, 18.4 mmol) in dimethylformamide (35 ml) is stirred at ambient temperature for 18 hours. The reaction mixture is partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic phase is washed with water and brine, dried over magnesium sulphate and evaporated. The crude product is purified by flash silica chromatography (elution with dichloromethane: methanol, 95:5 ) to afford {(S)-l-(tert-Butyl- diphenyl-silanyloxymethyl)-3-[3-(4-chloro-phenylsulfinyl)-azetidin-l-yl]-propyl}-carbamic acid tert-butyl ester. [MH] + 641.29.
(d) f(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-carbamic acid tert-butyl ester
A solution of {(S)-l-(tert-Butyl-diphenyl-silanyloxymethyl)-3-[3-(4-chloro-phenylsulfinyl)- azetidin-l-yl]-propyl}-carbarnic acid tert-butyl ester (2.7 g, 4.21 mmol) in THF (30 ml) is treated with a 1.0 M solution of tetrabutylammonium fluoride in THF (4.21 ml, 4.21 mmol) and the reaction mixture stirred at ambient temperature for 18 hours. The solvent is evaporated and the residue partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic phase is washed with water and brine, dried over magnesium sulphate and evaporated. The crude product is purified by flash silica chromatography (elution with dichloromethane: methanol, 95:5 ) to afford {(S)~3-[3-(4-Chloro-phenylsulfinyl)-azetidin-l-yl]- l-hydroxymethyl-propyl}-carbamic acid tert-butyl ester. [MH ]+ 403.18
(e) (S)-2-Amino-4-[3-(4-chloro-benzenesulfinyl)-azetidin-l-yl]-butan-l-ol
A solution of {(S)-3-[3-(4-Chloro-phenylsulfinyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}- carbamic acid tert-butyl ester (1.06 g, 2.63 mmol) in dichloromethane (30 ml) is treated with trifluoroacetic acid (7 ml) and stirred at ambient temperature for 2 hours. The solvent is evaporated and the residue partitioned between dichloromethane and sodium hydroxide solution. The DCM phase is dried over magnesium sulphate and evaporated to afford (S)-2- Amino-4-[3-(4-chloro-phenylsulfinyl)-azetidin-l-yl]-butan-l-ol. [M +H] 303.8
(f) l-{(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-l-yl]-l-hydroxymethyl-propyll-3-(3.5- dimethoxy-phen P-urea
A solution of (S)-2-Amino-4-[3-(4-chloro-phenylsulfinyl)-azetidin-l-yl]-butan-l-ol (0.1 g, 0.264 mmol) and dimethoxyphenylisocyanate (0.048 g, 0.264 mmol) in dichloromethane is stirred at ambient temperature for 2 hours. Te solvent is evaporated and the crude product is purified by flash silica chromatography (elution with dichloromethane: methanol, 99:1 to 95:5 ) to afford l-{(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-3-(3,5- dimethoxy-phenyl)-urea [MH]+ 484.32
Examples 2 to 6
The compounds of these Examples, namely l-{(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-l- yl]-l-hydroxymethyi-propyl}-3-(5-ethyl-[l,3,4]thiadiazol-2)-urea, l-{(S)-3-[3-(4-Chloro- benzenesulfinyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)- urea, l-{(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-3-(5- cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea, l-{(S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-l- yl]-l-hydroxymethyl-propyl}-3-(5-ethyl-isoxazol-3-yl)-urea and l-{(S)-3-[3-(4-Chloro- benzenesulfinyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-3-(3-ethyl-isoxazol-5-yl)-urea are prepared in a manner that is analogous to that described in Example 1.
Examples 7 to 12 The compounds of these Examples are prepared in a manner that is analogous to that described in Examples 1 to 6 but using ((S)-3-Iodo-l-methoxymethyl-propyl)-carbamic acid tert-butyl ester in place of [(S)-l-(tert-butyl-diphenyl-silanyloxymethyl)-3-iodo-propyl]- carbamic acid tert-butyl ester.
Examples 13 to 18
The compounds of these Examples are prepared in a manner that is analogous to that described in Examples 1 to 6 but using ((R)-3-iodo-l-methyl-propyl)-carbamic acid tert-butyl ester in place of [(S)-l-(tert-butyl-diphenyl-silanyloxymethyl)-3-iodo-propyl]-carbamic acid tert-butyl ester.
Example 19 l-{(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-3-(5-ethyl- [1,3 ,4] thiadiazol-2-yl)-urea:
(a) l-Benzhydryl-3-(4-chloro-phenylsulfanyl)-azetidine
A solution of 4-chlorothiophenol (3.0 g, 20.7 mmol) in dimethylformamide (30 ml) is treated with 60% sodium hydride dispersion in mineral oil (1.2 g, 30 mmol), stirred for 10 minutes at ambient temperature, then treated with a solution of methanesulfonic acid 1-benzhydryl- azetidin-3-yl ester (5.98 g, 18.8 mmol) in dimethylformamide (40 ml). The reaction mixture is heated at 60°C for 5 hours, then cooled to ambient temperature and partitioned between ethyl acetate and water. The organic phase is dried over magnesium sulphate and evaporated. The crude product is purified by flash silica chromatography (elution with iso-hexane: ether, 8:2 ) to afford l-Benzhydryl-3-(4-chloro-phenylsulfanyl)-azetidine as a pale yellow solid.
(b) 3-(4-Chloro-phenylsulfanyl)-azetidine
A solution of l-Benzhydryl-3-(4-chloro-phenylsulfanyl)-azetidine (0.62 g, 1.7 mmol) in dichloromethane (8 ml) cooled to -4°C, is treated with 1-chloroethoxycarbonyl chloride (0.4 ml, 2.68 mmol) and the reaction mixture allowed to warm to room temperature with stirring for 18 hours. The solvent is evaporated and the residue taken up in methanol (15 ml) and stirred at room temperature for a further 18 hours. The solvent is evaporated and the residue crystallized from methanol/diethylether to afford 3-(4-Chloro-phenylsulfanyl)-azetidine as a white solid.
(c) {(S)-l-(tert-Butyl-diphenyl-silanyloxymethyl)-3-[3-(4-chloro-phenylsulfanyl)-azetidin-l-yl]- propyl}-carbamic acid tert-butyl ester
A solution of 3-(4-Chloro-phenylsulfanyl)-azetidine (0.26 g, 1.1 mmol), [(S)-l-(tert-Butyl- diphenyl-silanyloxymethyl)-3-iodo-propyl]-carbamic acid tert-butyl ester (0.67 g, 1.21 mmol) and triethylamine (0.62 ml, 4.4 mmol) in dimethylformamide (12 ml) is stirred at ambient temperature for 18 hours. The reaction mixture is partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic phase is washed with water and brine, dried over magnesium sulphate and evaporated. The crude product is purified by flash silica chromatography (elution with dichloromethane: methanol, 95:5 ) to afford {(S)-l-(tert-Butyl- diphenyl-silanyloxymethyl)-3-[3-(4-chloro-phenylsulfanyl)-azetidin-l-yl]-propyl}-carbamic acid tert-butyl ester. [MH] + 625.26. (d) {(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-carbamic acid tert-butyl ester
A solution of {(S)-l-(tert-Butyl-diphenyl-silanyloxymethyl)-3-[3-(4-chloro-phenylsulfanyl)- azetidin-l-yl]-propyl}-carbamic acid tert-butyl ester (0.612 g, 0.978 mmol) in THF (7 ml) is treated with a 1.0 M solution of tetrabutylammonium fluoride in THF (0.98 ml, 0.98 mmol) and the reaction mixture stirred at ambient temperature for 18 hours. The solvent is evaporated and the residue partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic phase is washed with water and brine, dried over magnesium sulphate and evaporated. The crude product is purified by flash silica chromatography (elution with dichloromethane: methanol, 95:5 ) to afford {(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-l-yl]- l-hydroxymethyl-propyl}-carbamic acid tert-butyl ester. [M ]+ 387.15
(e) (S)-2-Amino-4-[3-(4-chloro-phenylsulfanyl)-azetidin-l-yl]-butan-l-ol
A solution of {(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}- carbamic acid tert-butyl ester (0.22 g, 0.568 mmol) in dichloromethane (7 ml) is treated with trifluoroacetic acid (3 ml) and stirred at ambient temperature for 3 hours. The solvent is evaporated and the residue partitioned between dichloromethane and sodium hydroxide solution. The DCM phase is dried over magnesium sulphate and evaporated to afford (S)-2- Amino-4-[3-(4-chloro-phenylsulfanyl)-azetidin-l-yl]-butan-l-ol.
(f) l-f(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-3-(5-ethyl- [1.3.4]thiadiazol-2-yl)-urea
A solution of (S)-2-Amino-4-[3-(4-chloro-phenylsulfanyl)-azetidin-l-yl]-butan-l-ol (0.12 g, 0.418 mmol) and (5-Ethyl-[l,3,4]thiadiazol-2-yl)-carbamic acid phenyl ester (0.104 g, 0.418 mmol) in DMSO (2 ml) is stirred at ambient temperature for 4 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic phase is dried over magnesium sulphate and evaporated. The crude product is purified by flash silica chromatography (elution with DCM: methanol, 95:5 to 90:10) to afford l-{(S)-3-[3-(4-Chloro-phenyl-sulfanyl)-azetidin- l-yl]-l-hydroxymethyl-propyl}-3-(5-ethyl-[l,3,4]thiadiazol-2-yl)-urea. [MH]+ 442.07. Examples 20 to 24
The compounds of these Examples, namely l-{(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-l- yl]-l-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, l-{(S)-3-[3-(4-Chloro- phenylsulf nyl) -azetidin- 1 -yl] - 1 -hydr oxymethyl-propyl }-3 -( 5 -cyclopr opyl-2-methyl-2H-pyrazol- 3-yl)-urea, l-{(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-3- (3,5-dimethoxy-phenyl)-urea and l-{(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-l-yl]-l- hydroxymethyl-propyl}-3-(5-ethyl-isoxazol-3-yl)-urea and l-{(S)-3-[3-(4-Chloro- phenylsulfanyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-3-(3-ethyl-isoxazol-5-yl)-urea are prepared in a manner that is analogous to that described in Example 19.
Example 25 l-{(S -3-[3-(4-Chloro-benzenesulfonyl)-azetidin-l-yl]-l-hydroxymethyl-propyll-3-(5-ethyl-
[1.3.4]thiadiazol-2-yl)-urea:
A solution of l-{(S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-3- (5-ethyl-[l,3,4]thiadiazol-2-yl)-urea ( 0.055 g, 0.124 mmol) in dichloromethane (9 ml) cooled to 15°C, is slowly treated with a solution oimeta chloroperbenzoic acid ( 0.052 mg, 0.3 mmol) in dichloromethane (2 ml) and stirred for 3 hours. The reaction mixture is diluted with dichloromethane and washed with saturated sodium bicarbonate solution and brine. The organic phase is dries over magnesium sulphate and evaporated. The crude product is purified by solid phase extraction using a 2 g Isolute SCX-3 cartridge (elution with methanol, then 5% ammonia in methanol) to afford l-{(S)-3-[3-(4-Chloro-benzenesulfonyl)-azetidin-l-yl]-l- hydroxymethyl-propyl}-3-(5-ethyl-[l,3,4]thiadiazol-2-yl)-urea. [MH] + 474.11
Examples 26 to 30
The compounds of these Examples, namely l-{(S)-3-[3-(4-Chloro-benzenesulfonyl)-azetidin-l- yl]-l-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, l-{(S)-3-[3-(4-Chloro- benzenesulf onyl) -azetidin- 1 -yl] - 1 -hydr oxymethyl-propyl}-3 - ( 5 -cyclopr opyl-2-methyl-2H- pyrazol-3-yl)-urea and l-{(S)-3-[3-(4-Chloro- benzenesulfonyl)-azetidin-l-yl]-l-hydroxymethyl- propyl}-3-(3,5-dimethoxy-phenyl)-urea, l-{(S)-3-[3-(4-Chloro-benzenesulfonyl)-azetidin-l-yl]- l-hydroxymethyl-propyl}-3-(5-ethyl-isoxazol-3-yl)-urea and l-{(S)-3-[3-(4-Chloro-benzene- sulfonyl)-azetidin-l-yl]-l-hydroxymethyl-propyl}-3-(3-ethyl-isoxazol-5-yl)-urea are prepared in a manner that is analogous to that described in Example 25. Compounds of formula lb that are also formula XXI
where Ar, X2, m, Q and R3 are as shown in Table 2 below, the methods of preparation being described hereinafter. The table also shows characterising mass spectrometry data. The compounds are all in free form.
TABLE 2
50
Preparation of intermediates
3-(3.4-Dichloro-phenoxy)-azetidine hydrochloride:
(a) l-Benzhydryl-3-(3,4-dichloro-phenoxy)-azetidine
A solution of 3,4 dichlorophenol (4.12 g, 25.3 mmol) in DMF (150 ml) under argon is treated with a 60% dispersion of sodium hydride in mineral oil (40.4 mmol) and the reaction mixture stirred for 10 minutes. A solution of Methanesulfonic acid l-benzhydryl-azetidin-3-yl ester (7.27 g, 22.96 mmol) in DMF (50 ml) is added and the reaction mixture left to stir at 60° C for 20 hours. The reaction mixture is portioned between ethyl acetate and water. The organic phase is washed with water (x2), dried over magnesium sulphate and evaporated. The crude product is purified by flash silica chromatography (elution with 1:4 ethylacetate/isohexane) to afford l-Benzhydryl-3-(3,4-dichloro-phenoxy)-azetidine. [M+H] 383.8 (b) 3-(3.4-Dichloro-phenoxy)-azetidine hydrochloride
A solution of l-Benzhydryl-3-(3,4-dichloro-phenoxy)-azetidine (2.14 g, 6.4 mmol) in dry dichloromethane (20 ml) is treated with 1-chloroethylchloroformate (0.832 ml, 7.7 mmol) with stirring for 4 hours. The solvent is evaporated and the residue dissolved in methanol and refluxed for 18 hrs. The methanol is evaporated to a saturated solution, and then treated with diethylether. The resulting precipitate is filtered and dried under vacuum to afford 3-(3,4- Dichloro-phenoxy)-azetidine hydrochloride. IH NMR (D6 DMSO, 400Mhz) δ 9.5 (2H, brS), 7.6 (IH, d), 7.2 (IH, s), 6.9 (IH, d), 5.1 (IH, m), 4.4 (2H, m), 3.95 (2H, m).
All other substituted phenoxy azetidine hydrochloride compounds, including 3-(4-chloro- phenoxy)-azetidine hydrochloride, are made analogously if they are not readily available from commercial sources.
Azetidin-3-yl-(4-chloro-phenyl)-methanone hydrochloride:
(a) (l-Benzhydryl-azetidin-3-yl)-(4-chloro-phenyl)-methanone
A solution of l-Benzhydryl-azetidine-3-carbonitrile (23.6 g, 95 mmol) in chlorobenzene (250 ml) under nitrogen is treated with a 1.0 M solution of 4-chlorophenylmagnesium bromide in diethylether (100 ml, 100 mmol) over one hour, ensuring the temperature does not exceed 30 °C. The stirred reaction mixture is heated to 60°C for 1 hour, then cooled back to ambient temperature and quenched with a saturated aqueous solution of ammonium chloride (250 ml). The organic phase is washed with brine, dried over magnesium sulphate, and evaporated to a yellow oil. The oil is dissolved in methanol (300 ml), treated with concentrated hydrochloric acid (25ml), and stirred at ambient temperature for 18 hours. The solvent is evaporated and the residue partitioned between ethyl acetate (250 ml) and saturated sodium bicarbonate solution (250 ml). The aqueous phase is extracted with more ethyl acetate and the combined organic phases, treated with magnesium sulphate and charcoal, filtered and evaporated to afford (l-Benzhydryl-azetidin-3-yl)-(4-chloro-phenyl)-methanone. [MH]+ 361.99
(b) Azetidin-3-yl-(4-chloro-phenyl)-methanone hydrochloride
A solution of (l-Benzhydryl-azetidin-3-yl)-(4-chloro-phenyl)-methanone (19.8 g, 54.8 mmol) in dichloromethane ( 250 ml), cooled to -4°C, is treated with 1-chloroethylchloroformate (8.0 ml, 73.8 mmol) and allowed to warm to ambient temperature. The reaction mixture is stirred for 18 hours and then evaporated. The residue is dissolved in methanol (220 ml) and stirred at ambient temperature for 3.5 hours. The methanol solution is concentrated and the product precipitated by addition of diethylether. The precipitate is collected by filtration and dries under high vacuum to afford Azetidin-3-yl-(4-chloro-phenyl)-methanone hydrochloride. [MH]+ 195.95.
Azetidin-3-yl-(4-chloro-benzoyl)-methanone hydrochloride and all other substituted benzoyl azetidine compounds are made analogously.
3-(4-Chloro-benzyl)-azetidinium trifluoroacetate salt:
(a) 3-(4-Chloro-benzoyl)-azetidine-l-carboxylic acid tert-butyl ester
A solution of azetidin-3-yl-(4-chloro-phenyl)-methanone hydrochloride (50 g, 210 mmol) in dioxa water 1:1 (800 ml) is added powdered sodium bicarbonate (61.7 g, 730 mmol) and the reaction mixture cooled to 10°C. Di-tbutyl-dicarbonate (52.6 g, 240 mmol) is added portion wise and the reaction mixture allowed to warm to room temperature with stirring for 1.5 hours. The reaction mixture is poured into water (1500 ml) and the resulting white precipitate filtered off and dried under vacuum to afford 3-(4-Chloro-benzoyl)-azetidine-l-carboxylic acid tert-butyl ester. Η NMR 400 MHz, CDC13, δ 1.45 (9H), 4.10 (IH), 4.20 (4H), 7.47 (2H), 7.80 (2H)
(b) 3-[(4-Chloro-phenyl)-hydroxy-methyl]-azetidine-l-carboxylic acid tert-butyl ester
A solution of 3-(4-Chloro-benzoyl)-azetidine-l-carboxylic acid tert-butyl ester (62.5 g, 210 mmol) in ethanol (1000 ml) cooled to 10°C is treated with sodium borohydride (9.5 g, 250 mmol). The reaction mixture is allowed to warm to room temperature and stirred for 2 hours. The reaction mixture is added to water and the precipitate collected by filtration, and dried under vacuum to afford 3-[(4-Chloro-phenyl)-hydroxy-methyl]-azetidine-l -carboxylic acid tert- butyl ester. Mpt 123-125°C.
(c) 3-[(4-Chloro-phenyl)-iodo-methyl]-azetidine-l-carboxylic acid tert-butyl ester Polymer supported triphenylphosphine (125 g, 370 mmol) is suspended in tetrahydrofuran: acetonitrile 9:1 (1000 ml) and treated with Iodine (95.2 g, 370 mmol) followed by stirring for 15 minutes. Imidazole (25.5 g, 370 mmol) is added followed by a solution of 3-[(4-Chloro- phenyl)-hydroxy-methyl]-azetidine-l-carboxylic acid tert-butyl ester (44.7 g, 150 mmol) in tetrahydrofuran (150 ml) and the reaction mixture stirred at ambient temperature for 20 hours. The reaction mixture is filtered through Celite™ filter material and the filtrate evaporated. The residue is taken up in chloroform and washed with sodium thiosulphate solution, water and brine. The solution is dried over magnesium sulphate and evaporated to provide 3-[(4-Chloro- phenyl)-iodo-methyl]-azetidine-l-carboxylic acid tert-butyl ester. Η NMR 400 MHz, CDC13, δ 1.35 (9H), 3.21 (IH), 3.37 ( IH), 3.60 ( 2H), 4.05 ( IH), 5.12 (IH), 7.20 (4H).
(d) 3-(4-Chloro-benzyl)-azetidine-l-carboxylic acid tert-butyl ester
A solution of 3-[(4-Chloro-phenyl)-iodo-methyl]-azetidine-l-carboxylic acid tert-butyl ester (58 g, 140 mmol) in dimethylsulphoxide (450 ml) is treated with sodium borohydride with cooling. The reaction mixture was stirred at room temperature for 20 hours, then quenched by the slow addition of water (1000 ml). The aqueous mixture is extracted into ethyl acetate, and the ethyl acetate phase washed with saturated brine, dried over magnesium sulphate and evaporated. The crude product is purified by flash chromatography using a biotage 75 column (eluant gradient isohexane:ethylacetate 9:1 to 85:15) to afford 3-(4-Chloro-benzyl)-azetidine- 1-carboxylic acid tert-butyl ester. Η NMR 400 MHz, CDC13, δ 1.35 (9H), 2.70 (IH), 2.80 ( 2H), 3.55 (2H), 3.90 (2H), 6.97 ( 2H), 7.17 (2H).
(e) 3-(4-Chloro-benzyl)-azetidinium trifluoroacetate salt
A solution of 3-(4-Chloro-benzyl)-azetidine-l-carboxylic acid tert-butyl ester (1.61 g, 5.71 mmol) in dichloromethane (20 ml) is treated with trifluoroacetic acid (20 ml) and stirred at ambient temperature for 1 hour. The reaction mixture is evaporated and then re-suspended in toluene and evaporated to dryness to afford 3-(4-Chloro-benzyl)-azetidinium trifluoroacetate salt. [MH]+ of free base 182.12.
All other substituted benzyl azetidine compounds are made analogously.
(5-Cyclopropyl-2-methyl-2H-pyrazol-3-yl)-carbamic acid phenyl ester:
A solution of 5-Cyclopropyl-2-methyl-2H-pyrazol-3-ylamine (3.0 g, 22 mmol) (65 ml) and sodium bicarbonate (2 g, 24 mmol) in THF is cooled to 0°C. Phenylchloroformate (3.4 g, 22 mmol) is added dropwise over 15 minutes. The reaction mixture is allowed to warm to ambient temperature and stirred for 5 hours, then filtered and the filtrate partitioned between ethyl acetate and water. The organic phase is washed with water, 5% aqueous citric acid solution and brine, dried over MgSO and evaporated to afford (5-Cyclopropyl-2-methyl-2H- pyrazol-3-yl)-carbamic acid phenyl ester. [M+H] 258.17.
(+/-)(lR.2R)-2-[3-(4-Chloro-phenoxy)-azetidin-l-ylmethyl]-cyclohexylamine:
(a) (+/-){(lR.2R)-2-[3-(4-Chloro-phenoxy)-azetidine-l-carbonyl]-cyclohexyl}-carbamic acid tert-butyl ester A solution of BOC-Cis-2amino-cyclohexylcarboxylic acid (1.0 g, 4.11mmol) and diisopropylethylamine (2.14ml, 12/33mmol) in dichloromethane is treated with [dimethylamino-([l,2,3]triazolo[4,5-b]pyridin-3-yloxy)-methylene]-dimethyl-ammonium hexafluoro phosphate (1.56g, 4.11mmol) and stirred at ambient temperature for 5 minutes. 3- (4-Chloro-phenoxy)-azetidine hydrochloride (0.984g, 4.32mmol) is added and the reaction mixture stirred for 18hours. The reaction mixture is diluted with dichloromethane and washed with saturated sodium bicarbonate solution and brine. The organic phase is dried over magnesium sulphate and evaporated. The crude product is purified by flash chromatography (eluant gradient 30% ethyl acetate in isohexane) to afford {(lR,2R)-2-[3-(4-Chloro-phenoxy)- azetidine-l-carbonyl]-cyclohexyl}-carbamic acid tert-butyl ester as a racemic mixture of optical isomers [M-BOC] 309.16
(b) (+/-){(lR.2R)-2-[3-(4-Chloro-phenoxy)-azetidin-l-ylmethyl]-cyclohexyl}-carbamic acid tert- butyl ester
A solution of {(lR,2R)-2-[3-(4-Chloro-phenoxy)-azetidine-l-carbonyl]-cyclohexyl}-carbamic acid tert-butyl ester (0.215 g, 0.52 mmol) in dry THF (5ml) cooled to -5°C is treated with a 1.0 M solution of LiAlH4 in THF (1.26 ml, 1.26 mmol) and the reaction mixture stirred at -5°C for 20 minutes and then for a further 1 hour at ambient temperature. The reaction mixture is quenched with saturated sodium sulphate solution and filtered through a Celite™ filter pad washing through with ethyl acetate. The filtrate is dried over magnesium sulphate and evaporated. The crude product is purified by flash chromatography (eluant 40% Ethyl acetate in isohexane) to afford {(lR,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-l-ylmethyl]-cyclohexyl}- carbamic acid tert-butyl ester as a racemic mixture of optical isomers [MH]+ 395.23
(c) (+/-)(lR.2R)-2-[3-(4-Chloro-phenoxy)-azetidin-l-ylmethyl]-cyclohexylamine
A solution of {(lR,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-l-ylmethyl]-cyclohexyl}-carbamic acid tert-butyl ester (0.078 g, 0.199 mmol) in dichloromethane (1 ml) is treated with trifluoroacetic acid ( 0.3ml) and the reaction mixture stirred at ambient temperature for 30 minutes. The solvent is evaporated and the residue taken up in dichloromethane and washed with 1 M NaOH solution. The organic phase is dried over magnesium sulphate and evaporated to afford (lR,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-l-ylmethyl]-cyclohexylamine as a racemic mixture of optical isomers. [MH]+ 295.19
l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-ethyll-cyclobutylamine:
(a) (l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-2-oxo-ethyl}-cyclobutyl)-carbamic acid tert- butyl ester A solution of (l-tert-Butoxycarbonylamino-cyclobutyl)-acetic acid (0.13 g, 0.567 mmol) ( synthesized by the method described in European Journal of Medicinal Chemistry (1999), 34(5), 363-380), and diisopropylethylamine (0.197 ml, 1.134 mmol) in dichloromethane is treated with [Dimethylamino-([l,2,3]triazolo[4,5-b]pyridin-3-yloxy)-methylene]-dimethyl- ammonium hexafluoro phosphate (0.216 g, 0.567 mmol) and stirred at ambient temperature for 5 minutes. 3-(4-Chloro-phenoxy)-azetidine hydrochloride is added and the reaction mixture stirred for 18 hours. The reaction mixture is diluted with dichloromethane and washed with saturated sodium bicarbonate solution and brine. The organic phase is dried over magnesium sulphate and evaporated. The crude product is purified by flash chromatography (eluant gradient isohexane.-ethylacetate 3:7 to 2:8) to afford (l-{2-[3-(4-Chloro-phenoxy)-azetidin-l- yl]-2-oxo-ethyl}-cyclobutyl)-carbamic acid tert-butyl ester. [MH]+ 395.16.
(b) (l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-ethyl}-cyclobutyl)-carbamic acid tert-butyl ester A solution of (l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-2-oxo-ethyl}-cyclobutyl)-carbamic acid tert-butyl ester (0.16 g, 0.405 mmol) in dry THF (5 ml) cooled to 0°C is treated with a 1.0M solution of LiAlH in THF (1.0 ml, 1.0 mmol) and the reaction mixture stirred at 0°C for 20 minutes and then for a further 1 hour at ambient temperature. The reaction mixture is quenched with saturated sodium sulphate solution and filtered through a Celite™ filter pad washing through with ethylacetate. The filtrate is dried over magnesium sulphate and evaporated. The crude product is purified by flash chromatography (eluant gradient dichloromethane:methanol 1:0 to 9:1) to afford (l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]- ethyl}-cyclobutyl)-carbamic acid tert-butyl ester. [MH]+ 381.20.
(c) l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-ethyll-cyclobutylamine
A solution of (l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-ethyl}-cyclobutyl)-carbamic acid tert- butyl ester ( 0.04g, 0.105mmol) in dichloromethane ( 3ml) is treated with trifluoroacetic acid ( 0.5ml) and the reaction mixture stirred at ambient temperature for 2 hours. The solvent is evaporated and the residue taken up in dichloromethane and washed with IM NaOH solution. The organic phase is dried over magnesium sulphate and evaporated to afford l-{2-[3-(4- Chloro-phenoxy)-azetidin-l-yl]-ethyl}-cyclobutylamine. [MH]+ 281.11
3-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-l,l-dimethyl-propylamine and {3-[3-(4-Chloro- phenoxy)-azetidin-l-yl]-l.l-dimethyl-propyll-methyl-amine:
(a) {3-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-l.l-dimethyl-3-oxo-propyl}-carbamic acid tert- butyl ester
A solution of 3-tert-Butoxycarbonylamino-3-methyl-butyric acid (0.58g, 2.67mmol) ( synthesized by the method described in Journal of Medicinal Chemistry (1991), 34(2), 633- 42. ), and diisopropylethylamine (1.39ml, δ.Olmmol) in dichloromethane is treated with [dimethylamino-([l,2,3]triazolo[4,5-b]pyridin-3-yloxy)-methylene]-dimethyl-ammonium hexafluoro phosphate ( l.Olg, 2.67mmol) and stirred at ambient temperature for 5 minutes. 3- (4-Chloro-phenoxy)-azetidine hydrochloride (0.68g, 2.67mmol) is added and the reaction mixture stirred for 18 hours. The reaction mixture is diluted with dichloromethane and washed with saturated sodium bicarbonate solution and brine. The organic phase is dried over magnesium sulphate and evaporated. The crude product is purified by flash chromatography (eluant gradient 25% to 50% ethylacetate: isohexane) to afford {3-[3-(4-Chloro-phenoxy)- azetidin-l-yl]-l,l-dimethyl-3-oxo-propyl}-carbamic acid tert-butyl ester [M-BOC] 283.08. (b) 3-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-l.l-dimethyl-propylamine A solution of {3-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-l,l-dimethyl-3-oxo-propyl}-carbamic acid tert-butyl ester (0.587g, 1.53mmol) in dry THF (5ml) cooled to -5oC is treated with a l.OM solution of LiAlH4 in THF (3.83ml, 3.83mmol) and the reaction mixture stirred at OoC for 30 minutes and then for a further 1 hour at ambient temperature. The reaction mixture is quenched with saturated sodium sulphate solution and filtered through a Celite™ filter pad washing through with ethyl acetate. The filtrate is dried over magnesium sulphate and evaporated. The crude product is purified by flash chromatography (eluant gradient dichloromethane:methanol 9:1 to 9:3) to afford as a 1:1 mixture of 3-[3-(4-Chloro-phenoxy)- azetidin-l-yl]-l,l-dimethyl-propylamine. [MH]+ 269.1 and {3-[3-(4-Chloro-phenoxy)-azetidin- l-yl]-l,l-dimethyl-propyl}-methyl-amine [MH]+ 283.12.
Preparation of final compounds
Example 31
(+/-)l-{(lR.2R)-2-[3-(4-Chloro-phenoxy)-azetidin-l-yl-methyl]-cyclohexyl)-3-(5-ethyl- n.3.41thiadiazol-2-yl)-urea:
A solution of (lR,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-l-ylmethyl]-cyclohexylamine (0.111 mg, 0.382 mmol) and (5-Ethyl-[l,3,4]thiadiazol-2-yl)-carbamic acid phenyl ester (0.100 g, 0.40 mmol) in dimethylsulphoxide (2 ml) is stirred at ambient temperature form 18 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic phase is dried over magnesium sulphate and evaporated. The crude product is purified by flash chromatography (eluant ethyl acetate) to afford l-{(lR,2R)-2-[3-(4-Chloro-phenoxy)-azetidin- l-ylmethyl]-cyclohexyl}-3-(5-ethyl-[l,3,4]thiadiazol-2-yl)-urea as a racemic mixture of optical isomers. [MH]+ 450.213 Examples 32 to 37
The compounds of these Examples, namely l-{(lR,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-l-yl- methyl]-cyclohexyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, l-{(lR,2R)-2-[3-(4-Chloro- phenoxy)-azetidin-l-yl-methyl]-cyclohexyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea, l-{(lR,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-l-yl-methyl]-cyclohexyl}-3-(5-cyclobutyl-2- methyl-2H-pyrazol-3-yl)-urea, l-{(lR,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-l-yl-methyl]- cyclohexyl}-3-(2-ethyl-2H-tetrazol-5-yl)-urea, l-{(lR,2R)-2-[3-(4-Chloro-phenoxy)-azetidin-l- yl-methyl]-cyclohexyl}-3-(5-ethyl-isoxazol-3-yl)-urea and l-{(lR,2R)-2-[3-(4-Chloro-phenoxy)- azetidin-l-yl-methyl]-cyclohexyl}-3-(3-ethyl-isoxazol-5-yl)-urea are prepared using procedures that are analogous to those used in Example 31.
Examples 38 to 51
The compounds of these Examples are prepared using procedures that are analogous to those used to prepare the compounds of Examples 31 to 37 but using the appropriate amine.
Examples 52 to 72
The compounds of these Examples are trans analogues of the compounds of Examples 31 to 51 respectively. They are prepared analogously but using the intermediate BOC-trans-2-amino- cyclohexylcarboxylic acid instead of BOC-cis-2-amino-cyclohexylcarboxylic acid.
Example 73 l-(l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-ethyl}-cyclobutyl)-3-(5-ethyl-[l,3.41thiadiazol-2- yl)-urea:
A solution of l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-ethyl}-cyclobutylamine (0.028 mg, 0.1 mmol) and (5-Ethyl-[l,3,4]thiadiazol-2-yl)-carbamic acid phenyl ester (0.028 g, 0.112 mmol) in dimethylsulphoxide (1.5 ml) is stirred at ambient temperature form 18 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic phase is dried over magnesium sulphate and evaporated. The crude product is purified by flash chromatography
(eluant gradient dichloromethane:methanol 98:2 to 93:7) to afford l-(l-{2-[3-(4-Chloro- phenoxy)-azetidin-l-yl]-ethyl}-cyclobutyl)-3-(5-ethyl-[l,3,4]thiadiazol-2-yl)-urea. [MH]+
436.12.
Examples 74 to 79
The compounds of these Examples, namely l-(l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]- ethyl}-cyclobutyl)-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, l-(l-{2-[3-(4-Chloro-phenoxy)- azetidin-l-yl]-ethyl}-cyclobutyl)-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea, l-(l-{2-[3- (4-Chloro-phenoxy)-azetidin-l-yl]-ethyl}-cyclobutyl)-3-(5-cyclobutyl-2-methyl-2H-pyrazol-3- yl)-urea, l-(l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-ethyl}-cyclobutyl)-3-(2-ethyl-2H- tetrazol-5-yl)-urea, l-(l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-ethyl}-cyclobutyl)-3-(5-ethyl- isoxazol-3-yl)-urea and l-(l-{2-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-ethyl}-cyclobutyl)-3-(3- ethyl-isoxazol-5-yl)-urea are prepared using procedures to those used in Example 73.
Examples 80 to 93
The compounds of these Examples are prepared using procedures that are analogous to those used to prepare the compounds of Examples 73 to 79 but using the appropriate amine.
Example 94 l-(3-r3-(4-Chloro-phenoxy)-azetidin-l-vn-l.l-dimethyl-propyl)-3-(5-ethyl-n.3.41thiadiazol-2- yl)-urea:
A solution of a 1:1 mixture of 3-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-l,l-dimethyl- propylamine and {3-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-l,l-dimethyl-propyl}-methyl-amine (0.069 mg) and 5-Ethyl-[l,3,4]thiadiazol-2-yl)-carbamic acid phenyl ester (0.067g, 0.26 mmol) in dimethylsulphoxide (2.0 ml) is stirred at ambient temperature form 18 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic phase is dried over magnesium sulphate and evaporated. The crude product is purified by flash chromatography (eluant gradient dichloromethane:methanol 98:2 to 90:10) to afford l-{3-[3-(4-Chloro- phenoxy)-azetidin-l-yl]-l,l-dimethyl-propyl}-3-(5-ethyl-[l,3,4]thiadiazol-2-yl)-urea. [MH]+ 424.13.
Examples 95 to 100
The compounds of these Examples, namely l-{3-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-l,l- dimethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, l-{3-[3-(4-Chloro-phenoxy)- azetidin-l-yl]-l,l-dimethyl-propyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea, l-{3-[3- (4-Chloro-phenoxy)-azetidin-l-yl]-l,l-dimethyl-propyl}-3-(5-cyclobutyl-2-methyl-2H-pyrazol- 3-yl)-urea, l-{3-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-l,l-dimethyl-propyl}-3-(2-ethyl-2H- tetrazol-5-yl')-urea, l-{3-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-l,l-dimethyl-propyl}-3-(5-ethyl- isoxazol-3-yl)-urea and l-{3-[3-(4-Chloro-phenoxy)-azetidin-l-yl]-l,l-dimethyl-propyl}-3-(3- ethyl-isoxazol-5-yl)-urea are prepared using procedures to those used in Example 94.
Examples 101 to 114 The compounds of these Examples are prepared using procedures that are analogous to those used to prepare the compounds of Examples 94 to 100 but using the appropriate amine.
Examples 115 to 98
The compounds of these Examples are prepared using procedures that are analogous to those used to prepare the compounds of Examples 31 to 37 and 52 to 58 respectively but using the appropriate starting materials.
Examples 129 to 142
The compounds of these Examples are prepared using procedures that are analogous to those used to prepare the compounds of Examples 31 to 37 and 52 to 58 respectively but using the appropriate starting materials.

Claims

1. A compound of formula la or lb
in free or salt form, where
Ar is phenyl optionally substituted by one or more substituents selected from halogen,
G-G-alkyl, cyano or nitro;
X1 is -S-, -S(=O)- or -S(=O)2-;
X2 is -C(=O)-, -O-, -CH2-, -S-, -S(=O)- or -S(=O)2-; m is 1, 2, 3 or 4;
R1 is hydrogen or G-Cs-alkyl optionally substituted by hydroxy, G-G-alkoxy, acyloxy, halogen, carboxy, G-G-alkoxycarbonyl, -N(R4)RS, -CON(R6)R7 or by a monovalent cyclic organic group having 3 to 15 atoms in the ring system;
Q has the formula Ra / \ C— C — where Ra is G-G-alkylene, or Q is -C(Rb)(Rc)- where Rb and Rc are independently G-G-alkyl or Rb and Rc together form a G-Go-cycloalkyl; Y is oxygen or sulfur;
R2 is hydrogen, G-Cs-alkyl or G-Go-cycloalkyl and R3 is G-Cs-alkyl substituted by phenyl, phenoxy, acyloxy or naphthyl, or R3 is G-Go-cycloalkyl optionally having a benzo group fused thereto, a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms, phenyl or naphthyl, said phenyl, phenoxy or naphthyl groups being optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, acyl, nitro, -SO2NH2, G-Cs- alkyl optionally substituted by G-G-alkoxy, G-G-haloalkyl, G-G-alkoxy, G-G- haloalkoxy, G-G-alkylthio, -SO2-G-G-alkyl, G-G-alkoxycarbonyl, G-G-acylamino optionally substituted on the nitrogen atom by G-Cs-alkyl, G-G-alkylamino, aminocarbonyl, G-G-alkylamino-carbonyl, di(G-G-alkyl)amino, di(G-Cs-alkyl)aminocarbonyl, di(G-G- alkyl)aminocarbonyl-methoxy, or R2 and R3 together with the nitrogen atom to which they are attached denote a heterocyclic group having 5 to 10 ring atoms of which 1, 2 or 3 are hetero atoms;
R4 and R5 are each independently hydrogen or G-Cs-alkyl, or R4 is hydrogen and R5 is hydroxy-G-G-alkyl, acyl, -SO2R8 or -CON(R6)R7, or R4 and R5 together with the nitrogen atom to which they are attached denote a 5-or 6-membered heterocyclic group;
R6 and R7 are each independently hydrogen or G-Cs-alkyl, or R6 and R7 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group; and
R8 is G-G-alkyl, G-G-haloalkyl, or phenyl optionally substituted by G-Cs-alkyl.
2. A compound according to claim 1, which is
(i) a compound of formula la in free or salt form, wherein Ar is phenyl substituted by halo; X1 is -S-, -S(=O)- or -S(=O)2-; m is 2; R1 is G-G-alkyl optionally substituted by hydroxy or G-G-alkoxy; Y is oxygen; R2 is hydrogen; and R3 is a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms; or (ii) a compound of formula lb in free or salt form, wherein Ar is phenyl substituted by halo; X2 is -O-, -C(=O)- or -CH2-; m is 1 or 2; Q has the formula Ra / \ C— C — where Ra is G-G-alkylene, or Q is -C(Rb)(Rc)- where Rb and Rc are independently G-Cs-alkyl or Rb and Rc together form a G-Go-cycloalkyl; R2 is hydrogen; and R3 is a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms.
3. A compound according to claim 1, which is (i) a compound of formula la in free or salt form, wherein Ar is phenyl substituted by halo, preferably chloro; X1 is -S-, -S(=O)- or -S(=O)2-; m is 2; R1 is G-G-alkyl optionally substituted by hydroxy or G-C -alkoxy; Y is oxygen; R2 is hydrogen; and R3 is a heterocyclic group having 5, 6 or 7 ring atoms of which one, two, three or four, are hetero atoms selected from nitrogen, oxygen and sulphur, said heterocyclic group being optionally substituted by G-C -alky, G-C -alkoxy or G-G-cycloalkyl; or (ii) a compound of formula lb in free or salt form, wherein Ar is phenyl substituted by halo, preferably chloro; X2 is -O-, -C(=O)- or -CH2-; m is 1 or 2; Q has the formula Ra / \ C— C where Ra is G-G-alkylene, or Q is -C(Rb)(Rc)- where Rb and Rc are independently G-G-alkyl or Rb and Rc together form a G-G-cycloalkyl; R2 is hydrogen; and R3 is a heterocyclic group having 5, 6 ox 7 ring atoms of which one, two, three or four, are hetero atoms selected from nitrogen, oxygen and sulphur, said heterocyclic group being optionally substituted by G-G-alkyl or G-G-cycloalkyl.
4. A compound according to claim 1 that is also either a compound of formula XX
where Ar, X1 and R3 are as shown in the following table:
or a compound of formula XXI
where Ar, X2, m, Q and R3 are as shown in the following table:
5. A compound according to any one of the preceding claims in combination with another drug substance which is an anti-inflammatory, a bronchodilator, an antihistamine or an anti- tussive substance.
6. A compound according to any one of the preceding claims for use as a pharmaceutical.
7. A pharmaceutical composition comprising as active ingredient a compound according to any one of claims 1 to 4.
8. The use of a compound according to any one of claims 1 to 4 for the manufacture of a medicament for the treatment of a condition mediated by CCR-3.
9. The use of a compound according to any one of claims 1 to 4 for the manufacture of a medicament for the treatment of an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease.
10. A process for the preparation of a compound of formula la or lb as claimed in claim 1 which comprises
(i) (A) for the preparation of compounds of formula la where R2 is hydrogen, reacting a compound of formula Ila
or a protected form thereof, where Ar, X1, m and R1 are as defined in claim 1, with a compound of formula III γ=C= — R3 III where Y and R3 are as defined in claim 1; or
(B) for the preparation of compounds of formula la where Y is oxygen, reacting a compound of formula Ila where Ar, X1, m and R1 are as defined in claim 1, with a compound of formula IV
where R2 and R3 are as defined in claim 1; or
(C) for the preparation of compounds of formula la where X1 is -S(=O)2-, oxidising a compound of formula la in protected form where X1 is -S- and Ar, m, R1, Y, R2 and R3 are as defined in claim 1;
(D) for the preparation of compounds of formula lb, reacting a compound of formula lib H Ar-X2- ^N-[-C-)^-Q- H2 lib H where Ar, X2, m and Q are as defined in claim 1, with a compound of formula IV where R2 and R3 are as defined in claim 1;
(E) for the preparation of compounds of formula lb where R2 is hydrogen, reacting a compound of formula lib where Ar, X2, m and Q are as defined in claim 1, with a compound of formula V 0=C= — R3 V where R3 is as defined in claim 1; or
(F) for the preparation of compounds of formula lb where X is -S(=O)2-, oxidising a compound of formula lb in protected form where X2 is -S- and Ar, m, Q, R2 and R3 are as defined in claim 1; and
(ii) recovering the product in free or salt form.
EP04765174A 2003-09-15 2004-09-14 1,3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases Not-in-force EP1663966B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL04765174T PL1663966T3 (en) 2003-09-15 2004-09-14 1,3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0321600A GB0321600D0 (en) 2003-09-15 2003-09-15 Organic compounds
GB0321599A GB0321599D0 (en) 2003-09-15 2003-09-15 Organic compounds
PCT/EP2004/010260 WO2005026113A1 (en) 2003-09-15 2004-09-14 1, 3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases

Publications (2)

Publication Number Publication Date
EP1663966A1 true EP1663966A1 (en) 2006-06-07
EP1663966B1 EP1663966B1 (en) 2007-06-20

Family

ID=34315436

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04765174A Not-in-force EP1663966B1 (en) 2003-09-15 2004-09-14 1,3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases

Country Status (13)

Country Link
US (1) US20070043013A1 (en)
EP (1) EP1663966B1 (en)
JP (2) JP2007505080A (en)
AT (1) ATE365155T1 (en)
AU (1) AU2004272275B2 (en)
BR (1) BRPI0414416A (en)
CA (1) CA2534550A1 (en)
DE (1) DE602004007150T2 (en)
ES (1) ES2286664T3 (en)
MX (1) MXPA06002870A (en)
PL (1) PL1663966T3 (en)
PT (1) PT1663966E (en)
WO (1) WO2005026113A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417801D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
EP2143714B1 (en) 2007-04-04 2013-06-05 Kowa Company, Ltd. Tetrahydroisoquinoline compound
JP6618120B2 (en) 2014-08-06 2019-12-11 塩野義製薬株式会社 Heterocyclic and carbocyclic derivatives having TrkA inhibitory activity
US10640495B2 (en) 2015-07-07 2020-05-05 Shionogi & Co., Ltd. Heterocycle derivatives having TrkA inhibitory activity
US10533006B2 (en) 2016-02-04 2020-01-14 Shionogi & Co., Ltd. Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity
CN110498750B (en) * 2019-09-02 2021-10-15 南通大学 Synthesis method of (R) -4-hydroxy-1-methoxybutyl-2-ylcarbamate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8509746D0 (en) * 1985-04-16 1985-05-22 Shell Int Research Preparing azetidine derivatives
JP2002510327A (en) * 1997-07-25 2002-04-02 メルク エンド カンパニー インコーポレーテッド Cyclic amine chemokine receptor activity modulator
CN1206219C (en) * 1998-12-18 2005-06-15 布里斯托尔-迈尔斯斯奎布药品公司 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2482100A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1363881A2 (en) * 2000-06-21 2003-11-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GB0117387D0 (en) * 2001-07-17 2001-09-05 Novartis Ag Organic compounds
AR041786A1 (en) * 2002-03-15 2005-06-01 Novartis Ag DERIVATIVES OF AZETIDINE AS ANTAGONISTS OF THE CCR-3 RECEIVER, A PROCESS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A MEDICINAL PRODUCT

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005026113A1 *

Also Published As

Publication number Publication date
JP2010265278A (en) 2010-11-25
CA2534550A1 (en) 2005-03-24
ATE365155T1 (en) 2007-07-15
US20070043013A1 (en) 2007-02-22
AU2004272275A1 (en) 2005-03-24
PT1663966E (en) 2007-09-26
JP2007505080A (en) 2007-03-08
MXPA06002870A (en) 2006-06-05
DE602004007150T2 (en) 2008-02-14
ES2286664T3 (en) 2007-12-01
AU2004272275B2 (en) 2009-02-26
PL1663966T3 (en) 2007-11-30
WO2005026113A1 (en) 2005-03-24
EP1663966B1 (en) 2007-06-20
DE602004007150D1 (en) 2007-08-02
BRPI0414416A (en) 2006-11-14

Similar Documents

Publication Publication Date Title
US6670379B2 (en) Piperidine compounds for use as ccr-3 inhibitors
AU2001281972A1 (en) Piperidine coumpounds for use as CCR-3 inhibitors
US7288537B2 (en) Azetidine derivatives as CCR-3 receptor antagonists
JP2010265278A (en) 1,3-disubstituted azetidine derivative for use as ccr-3 receptor antagonist in treatment of inflammatory and allergic disease
AU2005270308B2 (en) Azetidine derivatives as CCR-3 receptor antagonists
WO2003007939A1 (en) Azetidine derivatives and their use as ccr3 receptor antagonists
EP1778671B1 (en) Piperazine derivatives with ccr3 inhibiting activity
EP1791815B1 (en) Pyrrolidine derivatives acting as ccr3-receptor antagonists
WO2008092844A1 (en) Piperidin-acetamide derivatives for the treatment of inflammatory or allergic diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060418

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS AG

Owner name: NOVARTIS PHARMA GMBH

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004007150

Country of ref document: DE

Date of ref document: 20070802

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070920

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20070914

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20070402481

Country of ref document: GR

ET Fr: translation filed
REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2286664

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070920

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070620

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070620

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070930

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070620

26N No opposition filed

Effective date: 20080325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070914

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070914

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20090911

Year of fee payment: 6

Ref country code: NL

Payment date: 20090903

Year of fee payment: 6

Ref country code: PL

Payment date: 20090825

Year of fee payment: 6

Ref country code: PT

Payment date: 20090914

Year of fee payment: 6

Ref country code: TR

Payment date: 20090820

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20091006

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20090917

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20090819

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20100921

Year of fee payment: 7

Ref country code: IT

Payment date: 20100918

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100908

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20100908

Year of fee payment: 7

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20110314

BERE Be: lapsed

Owner name: NOVARTIS A.G.

Effective date: 20100930

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20110401

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110314

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20101018

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110404

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110401

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100914

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004007150

Country of ref document: DE

Representative=s name: DR. SCHOEN & PARTNER, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004007150

Country of ref document: DE

Representative=s name: DR. SCHOEN, NEYMEYR & PARTNER MBB, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100914

REG Reference to a national code

Ref country code: PL

Ref legal event code: LAPE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110914

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110914

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120531

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004007150

Country of ref document: DE

Effective date: 20120403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110914

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100914

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110915